

PROFESSOR P.R. FLATT
BSc, PhD, DSc, CBiol, FBS, CChem, FRSC, FHEA, MRIA

Personal

Name: Peter Raymond FLATT
Nationality: British
Position: Professor of Biomedical Sciences and Director Biomedical Research
Work address: School of Biomedical Sciences, Ulster University, Coleraine, Northern Ireland, BT52 1SA, U.K. (pr.flatt@ulster.ac.uk; 028-70-124419)

Education

1971-1974 BSc Biology and Chemistry (Aston University; First Class Honours)
1974-1977 PhD (Aston University) RIA of insulin and glucagon with studies on obesity-diabetes in mice. External examiner: Professor CN Hales, FRS
2018 DSc (Ulster University) Gut hormones and peptide therapeutics for diabetes

Employment

1978-1979 Royal Society European Exchange Postdoctoral Research Fellow
Department of Medical Cell Biology, University of Uppsala, Sweden
Role Ca^{2+} in pancreatic beta cell signal transduction- Professor B Hellman
1980-1989 Lecturer/Senior Lecturer
Department of Biochemistry, University of Surrey, Guildford
1989-present Professor of Biomedical Sciences and Head of Diabetes Research Group,
School of Biomedical Sciences, Ulster University
1992-1994 Director, Biomedical Sciences Research Centre, Ulster University
1994-1997 Head of School of Biomedical Sciences, Ulster University
2012-2017 Course Director, Ulster BSc (Hons) Biomedical Science Degree Courses
2017-present Director Biomedical Sciences Research Institute, Ulster University

Professional Qualifications and Awards

1989 Elected Fellow of the Institute of Biology (FIBiol now FBS)
1989 Elected Fellow of the Royal Society of Chemistry (FRSC)
1999 Recipient of Mary Jane Kugal Award of Juvenile Diabetes Federation International
2006 Recipient of Biochemistry Medal of Irish Section of the Biochemical Society
2006 Elected Member of the Royal Irish Academy (MRIA) – Ireland's premier Learned Body for Sciences and Humanities, founded in 1785
2006 Awarded Ulster University Senior Distinguished Research Fellowship
2007 Dorothy Hodgkin Award Lecturer of Diabetes UK
2009 Niall O'Meara Lecturer of Irish Endocrine Society
2010 Ernst-Friedrich Pfeiffer Memorial Lecture, European Association for the Study of Diabetes (AIDPIT)
2016 Steno Rounds Medal, Steno Diabetes Centre, Denmark

2017	Elected Fellow of Higher Education Academy (FHEA)
2022	2 nd ranking Worldwide Expert in Experimental Diabetes and 3 rd in Insulin Secretion according to independent assessment by Expertscape

Research Leadership

- Since 1989 responsible for several hundred of research workers, including academic staff, postdoctoral research fellows, research assistants, postgraduate research students and technical staff.
- Lead Ulster to award grade 4 in 1992 UFC Research Assessment Exercise under Unit of Assessment 11 and highest possible rating of 5* in 1996 RAE. 5* awarded in 2001 and 2008 REF, with ranking in both 2014 and 2021 within the top 2-6 UK Universities in Biomedical Sciences.
- Founding Head Diabetes Research Group at Ulster University that currently comprises 10 academic staff, 4 postdoctoral fellows and 12 PhD students.
- 96 PhD students supervised to successful completion within 4 years of registration
- 26 Past doctoral students currently hold tenured academic positions in UK or overseas and still actively pursue diabetes research.

Research and Publications

Original and world-leading experimental diabetes research on gut hormones, peptide therapeutics, drug discovery, cell therapy, beta-cell stimulus-secretion coupling and islet cell function has substantially advanced knowledge and generated significant interest from industry, resulting in publication (with >25,369 citations (h-index 75) of the following:

- 4 Multi-author edited international research texts
- 6 Edited proceedings
- 111 Reviews and book chapters
- 571 Original peer-reviewed scientific papers
- 493 Refereed conference abstracts
- 25 Patent families and inventions

Research discoveries

These include but are not restricted to the following examples with potential translational impact.

- Stable analogues of apelin, xenin, PYY, oxytocin, AVP, and esculentin-Cha for obesity-diabetes therapy
- Multiple acting peptide agonists for treatment of obesity-diabetes
- Incretin peptides for prevention of bone fractures and treatment of bone fragility
- Peptide analogues of GIP for treatment of obesity, insulin resistance and diabetes
- Gut peptide mimetics for treatment of disorders with dysfunctional synaptic transmission
- Novel GIP antagonist peptides for treatment of metabolic disease
- Glycated insulin as biomarker for prediabetes
- Electrofusion derived pancreatic beta cells for drug discovery and cellular screening - distributed worldwide by ECACC to >100 research laboratories and licenced following evaluation by 5 multi-national pharmaceutical companies
- Two related Impact Case Studies included in 2014 Ulster REF submission, rated 4*

Research Funding and Commercial Exploitation

- Research funding of over £25M from industry and a variety of other sources including Diabetes UK, The Wellcome Trust, European Fund for Study of Diabetes (EFSD), European Commission, Invest Northern Ireland, SAAD Trading Company, NI Department of Health & Social Services, SPUR, DENI, DEL and Ulster University.
- Academic Founder, Director and CSO of Diabetica Ltd, a company registered in Northern Ireland under number NI 33135.
- Winners of the prestigious 2008 inaugural Academic Enterprise Awards (ACES) Europe for Life Sciences for development of new approaches to diabetes therapy.
- Inventor on patents licensed through Innovation Ulster promising staged payments worth up to \$40M.

Research Presentations

- Approximately 600 research papers presented at national/international conferences organised by learned societies in more than 20 countries in Europe, North America, Middle East, Asia and Japan.
- Approximately 100 invited lectures delivered, including many to industry since 1982

Membership of Professional Associations

- Diabetes UK, European Association for the Study of Diabetes (EASD), Irish Endocrine Society, America Diabetes Association (ADA), Royal Irish Academy (RIA)

Other Indicators of Esteem and Work Promoting Science

- Member, Royal Irish Academy Advisory Committee for Assessment New Candidates
- Scientific Secretary, Committee of Medical and Scientific Section of British Diabetic Association
- Associate Editor, Frontiers of Endocrinology (Gut Endocrinology Section)
- Member of Diabetes UK Advisory and Professional Councils, and Diabetes UK Research Advisory Group
- Member Council EASD and EASD Langerhans Fellowship Committee
- Founding Chairman of EASD Islet Study Group
- UK Coordinator of EU funded Islet Research European Network (IREN) an Executive Committee of EU funded Islet Research European-Latin American Network (IRELAN)
- Member of Steering Committee of EASD Incretin Study Group
- Committee member Biochemical Society, Nutrition Society and Liaison Committees of British Endocrine Societies
- Member of Executive Committee and Honorary Treasurer Northern Ireland HPSS RRG in Endocrinology & Diabetes
- Member (or Chairman) Programme and Abstract Review Committees of Diabetes UK, EASD, Biochemical Society, Nutrition Society and ADA
- Member of Grants Review Committee of Diabetes UK and the RD Lawrence Fellowship and PhD studentship award committees.
- Chairperson of EFSD (Metabolic Toxicity) Grants Awards Committee and member of Grants Committee for Juvenile Diabetes Research Foundation (JDRF).

- Member MRC Expert Review Panel on UK Nutrition Research Partnership for Health and Disease
- Referee/advisor for grants submitted to The Wellcome Trust, MRC, Diabetes UK, EFSD, JDRF, Diabetes Research & Wellness Foundation (DRWF) plus many others.
- Member of Editorial Boards: Frontiers in Endocrinology (Associate Editor), Biochemical Journal, Journal of Endocrinology, International Journal of Peptides, World Journal of Diabetes
- Regular referee for Diabetes, Diabetologia, Diabetes Obesity Metabolism, Science, Nature, Molecular Cellular Endocrinology amongst others
- External examiner for the Medical Sciences Course (MSC) at the Faculty of Medicine and Health Sciences at United Arab Emirates (UAE) University, Al Ain. UAE.

National and International Profile

External examiner for 56 PhD theses in the field of islet and gut hormone research for 28 different Universities in UK, Europe, North America and Asia.

Established contacts with more than 350 scientists from 21 countries worldwide maintained through established networks, including EASD Islet Study Group, IREN and IRELAN. Joint research and publications with following:

- Institute of Clinical Biochemistry, Hannover Medical School, Germany (Prof S Lenzen).
- Department of Endocrinology, Karolinska Institute, Stockholm (Prof P-O Berggren).
- Oxford Centre for Diabetes Endocrinology & Metabolism, University of Oxford, UK (Prof P Rorsman)
- Bone Research Group, University of Angers, France (Dr G Mabileau)
- Research Division, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Dhaka (Prof AK Azad Kahn & Prof L Ali).
- Metabolic Unit, Royal Victoria Hospital, Belfast (Professor PM Bell).
- Department of Medicine, University of Barcelona, Spain (Prof R Gomis).
- Laboratory of Experimental Medicine, Brussels Free University, Belgium (Prof WJ Malaisse).
- School of Biomedical and Life Sciences, University of Lancaster (Prof C Holscher).
- Department of Biomedical Sciences, Curtin University, Perth, Australia (Prof P Newsholme).

Learning and Teaching

Considerable effort has been devoted to educating the next generation of scientists. Many of these have been inspired to become PhD students and gone on to develop successful careers in academia or industry. Teaching and related administrative responsibilities include:

- Teaching to University BSc (Hons) students studying Biomedical Sciences, Nutrition, Optometry, Pharmacy, Biological Sciences; MSc Biomed Sciences and Human Nutrition.
- Course Director, full-time and part-time BSc (Hons) courses in Biomedical Sciences (Ulster, 2011- 2017).
- Course Director, full-time and part-time MSc courses related to Biomedical Sciences (Ulster, 1989-1992).

PROFESSOR PETER R FLATT

EDITED BOOKS

1. Bailey, C.J. and Flatt, P.R. (Eds)
New Antidiabetic Drugs.
(49 contributors from 12 countries worldwide)
Smith Gordon & Co Ltd, London, p 320, 1990.
2. Flatt, P.R. (Ed)
Nutrient Regulation of Insulin Secretion.
(46 contributors from 8 countries worldwide)
Portland Press, London, p 415, 1992.
3. Flatt, P.R. and Lenzen, S. (Eds)
Frontiers of Insulin Secretion and Pancreatic B-Cell Research.
(240 contributors from 12 countries worldwide)
Smith-Gordon & Co Ltd, London, p. 630, 1994.
4. Ioannides, C. and Flatt, P.R. (Eds)
Drugs, Diet and Disease, Vol. 2, Mechanistic Approaches to Diabetes.
(33 contributors from 7 countries worldwide)
Ellis Horwood Ltd, Chichester, p. 380, 1999

EDITED PROCEEDINGS AND COLLECTIONS

1. Flatt, P.R. (Ed)
Nutrient Regulation of Insulin Secretion.
Special Colloquium of Biochemical Society, Guildford.
Biochem. Soc. Trans. 18: 101-127, 1990.
2. Flatt, P.R. (Ed)
Molecular mechanisms of insulin secretion and pancreatic B-cell dysfunction.
Special Colloquium of Biochemical Society, Belfast.
Biochem. Soc. Trans. 22: 1-41, 1994.
3. Flatt, P.R. (Ed)
Hypothalamic and metabolic effects of regulatory peptides.
Special Colloquium of Biochemical Society, Aberdeen.
Biochem. Soc. Trans. 24: 559-598, 1996.
4. Flatt PR and Conlon JM (Eds)
Newer peptide-based agents for treatment of patients with type 2 diabetes
Peptides 100: 1-281; 2018.
5. Flatt PR and Conlon JM (Eds)
Glucose-dependent insulinotropic polypeptide (GIP)
Peptides 125; 2020.
6. Flatt PR, Knopp FK, Tarasov AI (Eds)
Proglucagon-derived peptides
Front Endocrinol (Lausanne). 2021, e-book, Nov 11;12:776871. doi:
10.3389/fendo.2021.776871. PMID: 34858346; PMCID: PMC8631785.

PROFESSOR PETER R FLATT
REVIEWS AND BOOK CHAPTERS

1. Hellman, B., Andersson, T., Berggren, P.-O., Flatt, P.R., Gylfe, E. and Kohnert, K.-D.
The role of calcium in insulin secretion.
In: Hormones and Cell Regulation, Vol 3, Eds. J.E. Dumont and J. Nunez.
Elsevier/North Holland Biomedical Press: Amsterdam, New York and Oxford, pp 69-96, 1979.
2. Hellman, B., Abrahamsson, H., Andersson, T., Berggren, P.-O., Flatt, P.R. and Gylfe, E.
Participation of calcium pools in insulin secretion.
In: Diabetes 1979, Proceedings of the 10th Congress of the International Diabetes Federation, Vienna, September 9-14, 1979. International Congress Series No 500. Ed. W.K Waldhausl, Exerpta Medica: Amsterdam, Oxford & Princeton, pp 160-165, 1980.
3. Hellman, B., Abrahamsson, H., Andersson, T., Berggren, P.-O., Flatt, P.R., Gylfe, E. and Hahn, H.-J.
Calcium movements in relation to glucose-stimulated insulin secretion.
In: Biochemistry and Biophysics of the Pancreatic B-Cell. European Workshop, Brussels, 1979. Eds. W.J. Malaisse and I.-B. Taljedal, Georg Thieme Verlag: Stuttgart and New York, pp 122-130, 1980.
4. Marks, V. and Flatt, P.R.
Nutrition and Metabolism.
In: Scientific Foundations of Anesthesia, Edn. 3. Eds. C. Scurr and S. Feldman. William Heinemann Medical Books Ltd, pp 330-338, 1982.
5. Bailey, C.J. and Flatt, P.R.
Obesity: a case for biochemical manipulation.
Industrial Biotechnology 1: 6-7, 1982.
6. Bailey, C.J. and Flatt, P.R.
Advances in insulin therapy.
Pulse 43: 45-47, 1983.
7. Bailey, C.J. and Flatt, P.R.
Recent progress in diabetes.
Industrial Biotechnology 2: 11-12, 1983.
8. Flatt, P.R. and Bailey, C.J.
Neural involvement in the insulin response to feeding in obese hyperglycaemic (ob/ob) mice.
In: Lessons from Animal Diabetes, Eds. E. Shafrir and A. Renold, John Libbey and Company Ltd, London, pp 341-347, 1984.
9. Flatt, P.R., Bailey, C.J., Swanston-Flatt, S.K., Best, L., Kwasowski, P., Buchanan, K.D. and Marks, V.
Involvement of glucagon and GIP in the metabolic abnormalities of obese hyperglycaemic (ob/ob) mice.
In: Lessons from Animal Diabetes, Eds. E. Shafrir and A. Renold, John Libbey and Company Ltd, London, pp 341-347, 1984.

10. Flatt, P.R. and Bailey, C.J.
Dietary modulation of glucose intolerance in spontaneous obesity and diabetes.
In: Animal Models for Nutrition Research, Report of the Fifth Ross Conference on Medical Research. Ed. R.W. Phillips, Ross Laboratories: Ohio, pp 33-37, 1984.
11. Bailey, C.J. and Flatt, P.R.
Animal models of diabetes.
In: Recent Advances in Diabetes, Vol 2. Ed. M. Nattrass, Churchill Livingstone: Edinburgh, pp 71-89, 1986.
12. Bailey, C.J. and Flatt, P.R.
Antidiabetic drugs: New developments.
Industrial Biotechnology 6: 139-142, 1986.
13. Bailey, C.J. and Flatt, P.R.
The enteroinsular axis in models of hyperinsulinaemic and hypoinsulinaemic diabetes.
In: Frontiers in Diabetes Research: Lessons from Animal Diabetes, Vol 2. Eds. E. Shafir and A. Renold, John Libbey and Company Ltd, London, pp 217-224, 1988.
14. Morgan, L.M., Flatt, P.R. and Marks, V.
Nutrient regulation of the enteroinsular axis and insulin secretion.
Nutrition Research Review 1: 79-97, 1988.
15. Bailey, C.J., Flatt, P.R. and Marks, V.
Drugs inducing hypoglycaemia.
Pharmac. Ther. 42: 361-384, 1989.
16. Marks, V. and Flatt, P.R.
The metabolism of sugar and starches.
In: Dietary Starches and Sugars in Man.
Ed. J. Dobbing, Springer-Verlag, Berlin, pp 135-149, 1989.
17. Bailey, C.J. and Flatt, P.R.
Recent developments in the treatment of diabetes.
In: Resources and Applications of Biotechnology: The New Wave.
Ed. R. Greenshields, Macmillan Press Ltd, London, pp 239-252, 1989.
18. Flatt, P.R. (Ed)
Nutrient Regulation of Insulin Secretion.
Biochem. Soc. Trans. 18: 101-127, 1990.
19. Bailey, C.J. and Flatt, P.R.
Models for testing new hypoglycaemic drugs.
In: New Antidiabetic Drugs, Eds. C.J. Bailey and P.R. Flatt, Smith-Gordon and Company Ltd, London, pp 65-82, 1990.
20. Bailey, C.J. and Flatt, P.R.
Alkylglycidates.
In: New Antidiabetic Drugs, Eds. C.J. Bailey and P.R. Flatt, Smith-Gordon and Company Ltd, London, pp 231-236, 1990.
21. Bailey, C.J. and Flatt, P.R.
Animal models of non-insulin dependent diabetes mellitus.
In: Textbook of Diabetes, Eds. J. Pickup and G. Williams, Blackwell Scientific Publications,

- Oxford, pp 228-242, 1991.
22. Ioannides, C., Barnett, C.R., Ayrton, A.D. and Flatt, P.R.
Alterations of chemical toxicity in animal models of insulin-dependent diabetes.
In: *Frontiers in Diabetes Research: Lessons from Animal Diabetes*, Vol 3.
Ed. E. Shafrir, Smith-Gordon and Company Ltd, London, pp 306-312, 1991.
 23. Bailey, C.J., Flatt, P.R., Wilcock, C. and Day, C.
Antihyperglycaemic mechanism of action of metformin.
In: *Frontiers in Diabetes Research: Lessons from Animal Diabetes*, Vol 3.
Ed. E. Shafrir, Smith-Gordon and Company Ltd, London, pp 277-282, 1991.
 24. Swanston-Flatt, S.K., Day, C., Flatt, P.R. and Bailey C.J.
Evaluation of the antihyperglycaemic properties of traditional plant treatments for diabetes.
In: *Frontiers in Diabetes Research: Lessons from Animal Diabetes*, Vol 3.
Ed. E. Shafrir, Smith-Gordon and Company Ltd, London, pp 286-293, 1991.
 25. Flatt, P.R., Barnett, C.R., Shibier, O. and Swanston-Flatt, S.K.
Direct and indirect actions of nutrients in the regulation of insulin secretion from the pancreatic B-cells.
Proc. Nutr. Soc. 50: 559-566, 1991.
 26. Swanston-Flatt, S.K., Flatt, P.R., Day, C. and Bailey, C.J.
Traditional dietary adjuncts for the treatment of diabetes mellitus.
Proc. Nutr. Soc. 50: 641-651, 1991.
 27. Flatt, P.R. and Bailey, C.J.
Molecular mechanisms of insulin secretion and insulin action.
J. Biol. Educ. 25: 9-14, 1991.
 28. Berggren, P.-O., Rorsman, P., Efendic, S., Ostenson, C.G., Flatt, P.R., Nilsson, T., Arkhammar, P. and Juntti-Berggren, L.
Mechanisms of action of enteroinsular hormones, islet peptides and neural input on the insulin secretory process.
In: *Nutrient Regulation of Insulin Secretion*, Ed. P.R. Flatt, Portland Press Ltd, London, pp 289-318, 1992.
 29. Flatt, P.R., Bailey, C.J., Berggren, P.-O., Herberg, L. and Swanston-Flatt, S.K.
Defective insulin secretion in diabetes and insulinoma.
In: *Nutrient Regulation of Insulin Secretion*, Ed. P.R. Flatt, Portland Press Ltd, London, pp 341-386, 1992.
 30. Flatt, P.R.
Insulin: Jewel in the Pancreas.
Biochemist, 14: 12-14, 1992.
 31. Barnett, C.R., Flatt, P.R. and Ioannides, C.
Interrelationships between insulin-dependent diabetes mellitus and enhanced toxicity to environmental chemicals, drugs and carcinogens.
In: *Food, Nutrition and Chemical Toxicity*, Eds. D.V. Parke, C. Ioannides and R. Walker, Smith-Gordon and Co Ltd, London, pp 161-170, 1993.
 32. Flatt, P.R. and Barnett, C.R.
Endocrine pancreatic hormones.
In: *Encyclopaedia of Food Science, Food Technology and Nutrition*, Vol. 4, Eds. R. Macrae,

- R. Robinson and M. Sadler, Academic Press Ltd, London, pp 2402-2407, 1993.
33. Barnett, C.R. and Flatt, P.R.
Ketone bodies.
In: Encyclopaedia of Food Science, Food Technology and Nutrition, Vol. 4, Eds. R. Macrae, R. Robinson and M. Sadler, Academic Press Ltd, London, pp 2622-2626, 1993.
 34. Bailey, C.J. and Flatt, P.R.
Islet defects and insulin resistance in models of obese non-insulin dependent diabetes.
Diabetes Metabolism Reviews 9 (Suppl. 1): 43S-50S, 1993.
 35. Flatt, P.R. (Ed)
Molecular mechanisms of insulin secretion and pancreatic B-cell dysfunction.
Biochem. Soc. Trans. 22: 1-41, 1994.
 36. Barnett, C.R., Flatt, P.R., Bone, A.J. and Ioannides, C.
Hepatic cytochrome P450 profile in BB rats with spontaneous insulin-dependent diabetes mellitus.
In: Biochemistry, Biophysics and Molecular Biology of Cytochrome P450. Ed. M.C. Lechner, John Libbey Eurotext Ltd., London, pp. 547-550, 1994.
 37. Flatt, P.R., Abdelwahab, Y.H.A., Wilson, A.M., Barnett, C.R., O'Harte, F.P.M. and Swanston-Flatt, S.K.
Site-specific defects and glucose toxicity in pancreatic B-cell dysfunction of non-insulin-dependent diabetes mellitus.
In: Frontiers of Insulin Secretion and Pancreatic B-Cell Research.
Eds. P.R. Flatt and S. Lenzen, Smith-Gordon and Co Ltd, London, pp. 481-489, 1994.
 38. Strain, J.J., McDermott, B.M., Bailey, C.J. and Flatt, P.R.
Trace mineral levels in the tissues of streptozotocin-diabetic and obese hyperglycaemic mice.
In: Trace Elements in Health and Disease with Special Emphasis on Atherosclerosis. Ed. M.F. Reis, Smith-Gordon and Co Ltd, London, pp. 225-226, 1995.
 39. Barnett, C.R., Flatt, P.R. and Ioannides, C.
Drug metabolism and chemical toxicity in diabetes mellitus.
In: Trends in Comparative Biochemistry and Physiology,
Ed. J. Menon, Council of Scientific Research Integration, Research Trends, Trivandrum, India, pp. 973-984, 1995.
 40. Ioannides, C., Barnett, C.R., Irizar, A. and Flatt, P.R.
Drug metabolism and chemical toxicity in diabetes.
In: Drugs, Diet and Disease, vol. 2, Mechanistic Approaches to Diabetes.
Eds. C. Ioannides and P.R. Flatt, Ellis Horwood Ltd, Chichester, pp. 327-358, 1995.
 41. Bailey, C.J. and Flatt, P.R.
Development of antidiabetic drugs.
In: Drugs, Diet and Disease, vol. 2, Mechanistic Approaches to Diabetes.
Eds. C. Ioannides and P.R. Flatt, Ellis Horwood Ltd, Chichester, pp. 279-326, 1995.
 42. Flatt, P.R. (Ed)
Hypothalamic and metabolic effects of regulatory peptides.
Biochem. Soc. Trans. 24: 559-598, 1996.
 43. Ioannides, C., Barnett, C.R., Irizar, A. and Flatt, P.R.
Expression of cytochrome P450 proteins in disease.

- In: Cytochrome P450: Metabolic and Toxicological Aspects. Ed. C. Ioannides, CRC Press, Boca Raton, pp. 301-327, 1996.
44. Wilson, A.M., Barnett, C.R. and Flatt, P.R.
Altered secretory responsiveness of BRIN-BD11 cells cultured under hyperglycaemic conditions is not readily reversed by subsequent culture in lower glucose concentrations.
In: Physiology and Pathophysiology of the Islets of Langerhans.
Ed. B. Soria, Plenum Press, New York, pp. 379-384, 1997.
45. Bailey, C.J. and Flatt, P.R.
Animal syndromes of non-insulin-dependent diabetes mellitus.
In: Textbook of Diabetes, 2 edn., Eds. J. Pickup and G. Williams, Blackwell Scientific Publications, Oxford, pp 23.1-23.25, 1997.
46. Flatt, P.R.
Hormonal and neural control of endocrine pancreatic function.
In: Textbook of Diabetes, 2 edn., Eds. J. Pickup and G. Williams, Blackwell Scientific Publications, Oxford, pp 9.1-9.17, 1997.
47. Flatt, P.R., Abdel-Wahab, Y.H.A., Boyd, A.C., Barnett, C.R. and O'Harte, F.P.M.
Pancreatic B-cell dysfunction and glucose toxicity in non-insulin-dependent diabetes.
Proc. Nutr. Soc. 56: 243-262, 1997.
48. Gray, A.M. and Flatt, P.R.
Nature's own pharmacy: the diabetes perspective.
Proc. Nutr. Soc. 56: 507-517, 1997.
49. McClenaghan, N.H. and Flatt, P.R.
Engineering cultured insulin-secreting pancreatic B-cell lines.
J. Molec. Med. 77: 235-243, 1999.
50. Ioannides, C., Barnett, C.R. and Flatt, P.R.
The effects of experimental diabetes on the cytochrome P450 system and other metabolic pathways.
In: Experimental Models of Diabetes. Ed. J.H. McNeill,
CRC Press, Boca Raton, pp 79-116, 1999.
51. McClenaghan, N.H. and Flatt, P.R.
Physiological and pharmacological regulation of insulin release - insights offered through exploitation of insulin-secreting cell lines.
Diabetes, Obesity & Metabolism 1: 137-150, 1999.
52. Salgado, A.P., Santos, R.M., Pereira, F.C., Fernandes, A.P., Tome, A.R., Flatt, P.R., Ranasamy, R. and Rosario, L.M.
Glucose signalling in clonal insulin-secreting BRIN-BD11 cells: Role of Cytosolic Ca²⁺ and redox state.
In: Molecular Mechanisms of Transcellular Signalling, Ed. J.P. Thierry, IOS Press, Amsterdam, pp 212-220, 1999.
53. Bailey, C.J. and Flatt, P.R.
Animal syndromes resembling type 2 diabetes.
In: Textbook of Diabetes, Eds. J.C. Pickup and G. Williams, 3rd Edn, Blackwell Scientific Publications, Oxford, pp 25.1-25.30, 2003.

54. Flatt, P.R.
The hormonal and neural control of endocrine pancreatic function.
In: Textbook of Diabetes, Eds. J.C. Pickup and G. Williams, 3rd Edn, Blackwell Scientific Publications, Oxford, pp 11.1-11.21, 2003.
55. McClenaghan, N.H. and Flatt, P.R.
Hormones of the endocrine pancreas.
In: Encyclopedia of Food Sciences and Nutrition, Eds. B. Caballero, L. Trugo and P. Finglas, 2nd Edn., Academic Press, London, pp. 3150-3157, 2003.
56. Gault, V.A., Flatt, P.R. and O'Harte, F.P.M.
Glucose-dependent insulintropic polypeptide (GIP): anti-diabetic and anti-obesity potential. *Neuropeptides* 37: 253-263; 2003.
57. Gault, V.A., Flatt, P.R. and O'Harte, F.P.M.
Glucose-dependent insulintropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. *Biochem. Biophys. Res. Comm.* 308: 207-213; 2003.
58. Furman, B.L., Pyne, N., Flatt, P.R. and O'Harte, F.P.M.
Targeting beta cell cyclic adenosine monophosphate for the development of novel drugs for type 2 diabetes mellitus. *J. Pharm. Pharmacol.*, 56: 1-16; 2004.
59. Green, B.D., Gault, V.A., O'Harte, F.P.M. and Flatt, P.R.
Structurally modified analogues of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulintropic polypeptide (GIP) as future antidiabetic agents. *Curr. Pharm. Des.* 10: 3651-3662; 2004
60. Green, B.D., Irwin, N., Gault, V.A., O'Harte, F.P.M. and Flatt, P.R.
Development and therapeutic potential of incretin hormone analogues for type 2 diabetes. *Br. J. Diab. Vasc. Dis.* 5: 134-140; 2005.
61. Green, B.D., Flatt, P.R. and Bailey, C.J.
Inhibition of dipeptidyl peptidase IV activity as potential therapy of type 2 diabetes mellitus. *Expert Opin. Investig. Drugs*, 11: 525-539; 2006.
62. Flatt, P.R. and Green, B.D.
Nutrient regulation of insulin secretion in diabetes: Problems and potential solutions. *Biochem. Soc. Trans.* 34: 774-778; 2006.
63. Green, B.D., Flatt, P.R. and Bailey, C.J.
Dipeptidyl peptidase IV (DPP-IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. *Diab. Vasc. Dis. Res.* 3: 159-165; 2006.
64. Green, B.D., Flatt, P.R. and Bailey, C.J.
Glintins: dipeptidyl peptidase-4 (DPP-4) inhibitors to treat type 2 diabetes. *Future Prescriber* 8: 7-13; 2007.
65. Green, B.D. and Flatt, P.R.
Incretin hormone mimetics and analogues in diabetes therapeutics. *Best Pract. Res. Clin. Endocrinol. Metab.* 21: 497-516; 2007.
66. Flatt, P.R., Bailey, C.J and Green B.D.

- Dipeptidyl peptidase IV (DPPIV) and related molecules in type 2 diabetes.
Front. Biosci. 13: 3648-3660; 2008.
67. Flatt, P.R.
Dorothy Hodgkin Lecture 2008: Gastric inhibitory polypeptide (GIP) revisited – a new therapeutic target for obesity-diabetes?
Diabetic Med. 25: 759-764; 2008.
 68. McKillop, AM., Flatt PR.
Recent developments in the search for biomarkers for the diagnosis and monitoring of diabetes.
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2(3):172-177; 2008.
 69. Irwin, N., Flatt, P.R. and Gault, V.A.
GIP-based therapeutics for diabetes and obesity.
Current Chemical Biology 2: 61-68, 2008.
 70. Flatt, P.R., Bailey, C.J. and Green, B.D.
Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.
Curr. Drug Metab. 10: 125-137; 2009.
 71. Irwin, N., Moodley, M., Flatt, P.R.
Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetes.
Br. J. Diabetes Vasc. Dis. 9 : 44-52 ; 2009.
 72. Irwin, N. and Flatt, P.R.
Therapeutic potential for GIP receptor agonists and antagonists.
Best Pract. Res. Clin. Endocrinol. Metab. 23: 499-512; 2009.
 73. Flatt, P.R., Day, C. and Bailey, C.J.
Bariatric surgery to treat diabetes.
Br. J. Diabetes Vasc. Dis. 9: 103-107; 2009.
 74. Irwin, N. and Flatt, P.R.
Evidence for beneficial effects of compromised GIP action in obesity-diabetes and possible therapeutic implications.
Diabetologia 52: 1724-1731; 2009.
 75. Irwin N, Gault VA and Flatt PR.
Therapeutic potential of the original incretin hormone GIP: Diabetes, Obesity, Osteoporosis and Alzheimer's Disease.
Expert Opin. Investig. Drugs 19: 1039-1048; 2010.
 76. Bailey, C.J., Green, B.D. and Flatt, P.R.
Fixed-dose combination therapy for type 2 diabetes: Sitagliptin plus pioglitazone.
Expert Opin. Investig. Drugs 19: 1017-1025; 2010.
 77. Green, B.D., Bailey, C.J. and Flatt, P.R.
Gliptin therapies for inhibiting dipeptidyl peptidase-4 in type 2 diabetes.
European Endocrinol. 6: 26-30; 2010.
 78. McKillop, A.M. and Flatt, P.R.
Emerging applications of genomic and metabolic profiling in diabetic clinical medicine.
Diabetes Care 34: 2624-2630; 2011.

79. Kelly, C., McClenaghan, N.H. and Flatt, P.R.
Role of islet structure and cellular interactions in the control of insulin secretion.
Islets, 3: 41-47; 2011.
80. Abed A, Critchlow C, Flatt PR, McClenaghan NH and Kelly C.
Directed differentiation of progenitor cells towards an islet cell phenotype.
Am. J. Stem Cells 1(3): 196-204; 2012.
81. Ojo, O. O., Flatt, P. R, Abdel-Wahab, Y. H. A and Conlon, J. M.
Insulin-releasing peptides.
In: Handbook of Biologically Active Peptides, Section: Amphibian Skin Peptides, Ed. A.Kastin, 2nd Edn, Elsevier Academic Press: Amsterdam. pp. 364-370, 2013.
82. Irwin N and Flatt PR
Gastric inhibitory polypeptide (GIP).
In: Handbook of Biologically Active Peptides, Section: Gastrointestinal Peptides, Ed. A.Kastin, 2nd Edn, Elsevier Academic Press: Amsterdam. pp. 1227-1235, 2013.
83. Irwin, N. and Flatt, P.R.
Enteroendocrine hormone mimetics for the treatment of obesity and diabetes.
Curr Opin Pharmacol. 13: 989-995; 2013.
84. Conlon, J.M., Mechkarska, M., Lukic, M.L. and Flatt, P.R.
Potential therapeutic applications of multifunctional host-defense peptides from frog skin as anti-cancer, anti-viral, immunomodulatory, and anti-diabetic agents.
Peptides. 57: 67-77; 2014.
85. Irwin, N. and Flatt, P.R.
New perspectives on exploitation of incretin peptides for treatment of diabetes and related disorders.
World J. Diabetes 6(215): 1285-1295; 2015.
86. Mabillean, G., Chappard, D., Flatt, P.R. and Irwin, N.
Effects of antidiabetic drugs on bone metabolism.
Expert Rev Endocrinol. Metab. 10: 663-675; 2015.
87. Moran, B.M., Flatt, P.R. and McKillop, A.M.
G-protein coupled receptors: signalling and regulation by lipid agonists for improved glucose homeostasis.
Acta Diabetologica, 53: 177-188; 2016.
88. Flatt PR and Conlon JM
Newer peptide-based agents for treatment of patients with type 2 diabetes (Editorial)
Peptides 100: 1-2; 2018.
89. Conlon J.M., Mechkarske M., Abdel-Wahab, Y.H.A. and Flatt, P.R.
Peptides from frog skin with potential for development into agents for type 2 diabetes therapy.
Peptides, 100: 275-281; 2018.
90. Pathak V., Flatt, P.R. and Irwin, N.
Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of type 2 diabetes and obesity.
Peptides, 100: 229-235; 2018.

91. Pathak V, Flatt PR and Irwin N
The entero-insular axis – contribution to obesity-diabetes and its treatment.
In Nutrition and Diabetes: Pathophysiology and management. Ed Opara EC, 2nd Edn., CRC Press, Boca Raton, 2018.
92. Kahn D, Moffett CR, Flatt PR and Kelly C
Role of intra-islet peptides in beta cell regulation and therapy.
Peptides, 100: 212-218; 2018.
93. Lafferty R, Flatt PR and Irwin N
Emerging therapeutic potential of peptide YY for obesity-diabetes.
Pancreas, 100: 269-274; 2018.
94. Conlon JM, Moffett RC, Leprince J and Flatt PR
Identification of components in frog skin secretions with therapeutic potential as anti-diabetic agents.
Methods in Molecular Biology 1719: 319-333;2018.
95. Green AD, Vasu S and Flatt PR
Cellular models for beta cell function and diabetes gene therapy.
Acta Physiol 222: e13012; 2018.
96. Irwin N, Gault VA, O'Harte FPM, Flatt PR.
Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes.
Peptides. 2020 Nov 13;170203. doi: 10.1016/j.peptides.2019.170203.
97. Flatt PR, Conlon JM.
GIP renaissance (Editorial).
Peptides. 2020; 125:170266. doi:10.1016/j.peptides.2020.170266
98. Muller TD, Finan B, Bloom SR, D'Alessio D, Dricker DJ, Flatt PR, Fritsche A, Gribble F, Grill JJ, Hanener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwart TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RC, Tschop MH
Glucagon-like peptide 1 (GLP-1).
Mol Metab. 2019; 30:72-130. doi:10.1016/j.molmet.2019.09.010
99. Lafferty RA, O'Harte FPM, Irwin N, Gault VA, Flatt PR.
Proglucagon-Derived Peptides as Therapeutics.
Front Endocrinol (Lausanne). 2021 May 18;12:689678. doi: 10.3389/fendo.2021.689678. PMID: 34093449; PMCID: PMC8171296.
100. Tanday N, Flatt PR, Irwin N.
Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands.
Br J Pharmacol. 2021 Apr 6. doi: 10.1111/bph.15485. Epub ahead of print. PMID: 33822370.
101. Lafferty RA, Flatt PR, Irwin N.
Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes.
Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):253-261. doi: 10.1097/MED.0000000000000612. PMID: 33395088.
102. Lafferty R, O'Harte FPM, Irwin N, Flatt PR, Gault VA.
Structurally modified gut peptides hormone mimetics for obesity and diabetes.
Comprehensive Pharmacology, in press.

103. Tanday N, Flatt PR, Irwin N.
Amplifying the antidiabetic actions of GLP-1: potential benefits of new adjunct therapies. *Diabet Med*. 2021 Sep 25:e14699. doi: 10.1111/dme.14699. Epub ahead of print. PMID: 34562330.
104. Conlon JM, Flatt PR, Bailey CJ.
Recent advances in peptide-based therapy for Type 2 diabetes and obesity. *Peptides*. 2021 Nov;145:170652. doi: 10.1016/j.peptides.2021.170652. Epub 2021 Sep 20. PMID: 34555424.
105. Flatt PR, Knop FK, Tarasov AI.
Proglucagon-Derived Peptides. *Front Endocrinol (Lausanne)*. 2021 Nov 11;12:776871. doi: 10.3389/fendo.2021.776871. PMID: 34858346; PMCID: PMC8631785.
106. Conlon JM, O'Harte FPM, Flatt PR.
Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review. *Peptides*. 2022 Jan;147:170706. doi: 10.1016/j.peptides.2021.170706. Epub 2021 Nov 30. PMID: 34861327.
107. Khan D, Moffett RC, Flatt PR, Tarasov AI.
Classical and non-classical islet peptides in the control of β -cell function. *Peptides*. 2022 Apr;150:170715. doi: 10.1016/j.peptides.2021.170715. Epub 2021 Dec 24. PMID: 34958851.
108. Klempel N, Thomas K, Conlon JM, Flatt PR, Irwin N. Alpha-cells and therapy of diabetes: Inhibition, antagonism or death? *Peptides*. 2022 Nov;157:170877. doi: 10.1016/j.peptides.2022.170877. Epub 2022 Sep 12. PMID: 36108978.
109. Thomas KG, Klempel NJ, Flatt PR, Bailey CJ, Moffett RC. Synthalin: a lost lesson for glucagon suppression in diabetes therapeutics. *J Pharm Pharmacol*. 2023 Mar 4:rgad010. doi: 10.1093/jpp/rgad010. Epub ahead of print. PMID: 36879406.
110. Bailey CJ, Flatt PR, Conlon JM. An update on peptide-based therapies for type 2 diabetes and obesity. *Peptides*. 2023 Mar;161:170939. doi: 10.1016/j.peptides.2023.170939. Epub 2023 Jan 3. PMID: 36608818.
111. Zhu W, Tanday N, Flatt PR, Irwin N. Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes. *Peptides*. 2023 Feb;160:170923. doi: 10.1016/j.peptides.2022.170923. Epub 2022 Dec 9. PMID: 36509169.

PROFESSOR PETER R FLATT

FULL SCIENTIFIC PAPERS

1. Atkins, T.W., Best, L.C., Flatt, P.R., Bailey, C.J. and Matty, A.J.
Effects of pilocarpine on insulin secretion in normal and obese hyperglycaemic mice (ob/ob) and in the rat.
Gen. Pharmac. 6: 43-47, 1975.
2. Bailey, C.J., Flatt, P.R., Atkins, T.W. and Matty, A.J.
Immunoreactive insulin in bile and pancreatic juice of rat.
Endocrinologia experimentalis 10: 101-111, 1976.
3. Flatt, P.R. and Swanston-Flatt, S.K.
Rapid production of glucagon antisera in the guinea pig.
Horm. Metab. Res. 11: 593-594, 1979.
4. Flatt, P.R., Gylfe, E. and Hellman, B.
Dissociation between ⁴⁵Ca uptake and insulin release: Evidence for an inhibitory pool of calcium in the beta cell plasma membrane.
Biochem. Soc. Trans. 7: 1097-1100, 1979.
5. Flatt, P.R., Swanston-Flatt, S.K. and Bailey, C.J.
Glucagon antiserum: A tool to investigate the role of circulating glucagon in obese hyperglycaemic mice (ob/ob).
Biochem. Soc. Trans. 7: 911-913, 1979.
6. Flatt, P.R., Boquist, L. and Hellman, B.
Calcium and pancreatic B-cell function: The mechanism of insulin secretion studied with the aid of lanthanum.
Biochem. J. 190: 361-372, 1980.
7. Flatt, P.R., Berggren, P.-O., Gylfe, E. and Hellman, B.
Calcium and pancreatic B-cell function: Demonstration of lanthanide-induced inhibition of insulin secretion independent of modifications in transmembrane Ca²⁺ fluxes.
Endocrinology 107: 1007-1013, 1980.
8. Bailey, C.J. and Flatt, P.R.
Insulin and glucagon during pentobarbitone anaesthesia.
Diabetes Metab. 6: 91-95, 1980.
9. Flatt, P.R., Bailey, C.J. and Buchanan, K.D.
Circulating immunoreactive glucagon concentrations in aging obese-hyperglycaemic (ob/ob) mice.
Biochem. Soc. Trans. 8: 57-58, 1980.
10. Flatt, P.R., Buchanan, K.D. and Bailey, C.J.
Glucagon and diabetes: Evidence for marked insensitivity to local regulation of A-cell function by endogenous insulin in obese-hyperglycaemic (ob/ob) mice.
Biochem. Soc. Trans. 8: 58-59, 1980.

11. Bailey, C.J., Day, C., Flatt, P.R. and Atkins, T.W.
Effect of repeated sodium pentobarbitone administration on glucose homeostasis in mice.
Gen. Pharmac. 11: 303-305, 1980.
12. Andersson, T., Berggren, P.-O. and Flatt, P.R.
Subcellular distribution of zinc in islet B-cell fractions.
Horm. Metab. Res. 12: 275-276, 1980.
13. Flatt, P.R. and Swanston-Flatt, S.K.
Production and evaluation of antibodies to glucagon-albumin conjugates in the guinea pig.
Acta Physiol. Scand. 108: 317-319, 1980.
14. Flatt, P.R.
Selection of albumin preparations for use in the radioimmunoassay of glucagon.
Medical Laboratory Sciences 37: 175-177, 1980.
15. Flatt, P.R. and Bailey, C.J.
Further evidence for a gene-dosage effect in lean heterozygous (ob/+) mice.
Biochem. Soc. Trans. 8: 588-589, 1980.
16. Swanston-Flatt, S.K. and Flatt, P.R.
The effect of pregnancy, ovariectomy, the administration of ethynyloestradiol and oestradiol on the intestinal transfer of folic acid in the rat.
Biochem. Soc. Trans. 8: 589-590, 1980.
17. Flatt, P.R., Gylfe, E. and Hellman, B.
Thulium binding to the pancreatic B-cell membrane.
Endocrinology 108: 2258-2263, 1981.
18. Flatt, P.R. and Bailey, C.J.
Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice.
Diabetologia 20: 573-577, 1981.
19. Flatt, P.R. and Bailey, C.J.
Development of glucose intolerance and impaired plasma insulin response to glucose in obese hyperglycaemic (ob/ob) mice.
Horm. Metab. Res. 13: 556-560, 1981.
20. Flatt, P.R. and Swanston-Flatt, S.K.
Stimulation of antiglucagon antibodies in rabbits and guinea pigs using a glucagon-carbodiimide-albumin conjugate.
Endocrinologia experimentalis 15: 3-17, 1981.
21. Flatt, P.R.
Miniaturized technique for the rapid extraction of plasma glucagon for radioimmunoassay.
Clin. Chim. Acta. 110: 127-129, 1981.
22. Flatt, P.R. and Bailey, C.J.
Importance of the enteroinsular axis for the insulin-secretory response to glucose in obese hyperglycaemic (ob/ob) mice.
Biochem. Soc. Trans. 9: 220-221, 1981.
23. Bailey, C.J. and Flatt, P.R.
Effect of age on the plasma glucose and insulin responses to glucagon in mice.

- Biochem. Soc. Trans. 9: 221-222, 1981.
24. Bailey, C.J., Flatt, P.R. and Atkins, T.W.
Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice.
Int. J. Obesity 6: 11-21, 1982.
 25. Flatt, P.R. and Bailey, C.J.
Plasma glucose and insulin responses to glucagon and arginine in Aston ob/ob mice: Evidence for a selective defect in glucose-mediated insulin release.
Horm. Metab. Res. 14: 127-130, 1982.
 26. Bailey, C.J. and Flatt, P.R.
Hormonal control of glucose homeostasis during development and ageing in mice.
Metabolism 31: 238-246, 1982.
 27. Bailey, C.J. and Flatt, P.R.
Characterisation of the insulin-secretory defect in fed adult Aston ob/ob mice: Lack of effect of glibenclamide.
Biochem. Soc. Trans. 10: 28-29, 1982.
 28. Flatt, P.R., and Bailey, C.J.
Effect of age and glucose priming on the insulin-secretory response to glucose in fed obese hyperglycaemic (ob/ob) mice.
Biochem. Soc. Trans. 10: 29-30, 1982.
 29. Flatt, P.R., Bailey, C.J. and Buchanan, K.D.
Regulation of plasma immunoreactive glucagon in obese hyperglycaemic (ob/ob) mice.
J. Endocr. 95: 215-227, 1982.
 30. Flatt, P.R. and Bailey, C.J.
Role of dietary factors in the hyperinsulinaemia of genetically obese hyperglycaemic (ob/ob) mice.
J. Nutr. 112: 2212-2216, 1982.
 31. Flatt, P.R., Tan, K., Bailey, C.J., Swanston-Flatt, S.K., Marks, V. and Webster, J.D.
Plasma glucose and insulin concentrations following implantation and surgical resection of a transplantable rat insulinoma.
Biochem. Soc. Trans. 10: 273-274, 1982.
 32. Ostensen, C.-G., Swenne, I., Flatt, P.R. and Berggren, P.-O.
Insulin antibody production in guinea pigs is accompanied by disturbances in pancreatic islet morphology and glucagon secretion.
Diabete Metab. 8: 241-247, 1982.
 33. Swanston-Flatt, S.K., Flatt, P.R. and Blair, J.A.
Folic acid absorption in the proximal jejunum of streptozotocin-diabetic and cortisone-treated rats.
Biochem. Soc. Trans. 10: 271-272, 1982.
 34. Bailey, C.J. and Flatt, P.R.
Age-effects on cortisone-induced insulin antagonism in mice.
Biochem. Soc. Trans. 10: 270-271, 1982.
 35. Flatt, P.R. and Bailey, C.J.

- Glucose and insulin responses to conditioned feeding in lean and genetically obese hyperglycaemic (ob/ob) mice.
Metabolism 32: 504-509, 1983.
36. Flatt, P.R., Bailey, C.J., Kwasowski, P., Swanston-Flatt, S.K. and Marks, V.
Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice.
Diabetes 32: 433-435, 1983.
37. Flatt, P.R., Bailey, C.J. and Swanston-Flatt, S.K.
Heterogeneity of glucagon-like immunoreactive peptides (GLI) in the intestine of obese hyperglycaemic (ob/ob) mice.
Horm. Metab. Res. 15: 308-309, 1983.
38. Flatt, P.R. and Bailey, C.J.
Plasma glucose and insulin responses to voluntary food ingestion in genetically obese hyperglycaemic (ob/ob) mice.
Biochem. Soc. Trans. 11: 285-286, 1983.
39. Flatt, P.R., Kwasowski, P., Swanston-Flatt, S.K., Marks, V. and Bailey, C.J.
Immunoreactive GIP in plasma and intestine of obese hyperglycaemic (ob/ob) mice.
Scand. J. Gastroenterol. 18 (Suppl. 83): 213-214, 1983.
40. Flatt, P.R. and Swanston-Flatt, S.K.
Effects of decapsulation on superficial and intracellular ⁴⁵Ca uptake by isolated mouse pancreatic islets.
Biomedical Research 4: 557-566, 1983.
41. Flatt, P.R. and Bailey, C.J.
Neuroendocrine reflexes in the insulin secretory response to feeding in lean and genetically obese (ob/ob) mice.
Biochem. Soc. Trans. 11: 284-285, 1983.
42. Flatt, P.R. and Berggren, P.-O.
Distribution of chromium in the tissues of normal and genetically diabetic mice.
Biochem. Soc. Trans. 11: 722, 1983.
43. Flatt, P.R., Bailey, C.J. and Swanston-Flatt, S.K.
Increased content of low molecular weight enteroglucagon in the small intestine of genetically obese hyperglycaemic (ob/ob) mice.
Biochem. Soc. Trans. 11: 720-721, 1983.
44. Flatt, P.R., Bailey, C.J., Kwasowski, P., Page, T., Gee, S.M., Swanston-Flatt, S.K. and Marks, V.
Hyperglycaemia in genetically obese hyperglycaemic (ob/ob) mice: Relationship to hyperphagia and intestinal K-cell insulin insensitivity.
Scand. J. Gastroenterol. 18 (Suppl. 87): 110-111, 1983.
45. Flatt, P.R. and Bailey, C.J.
Dietary components and the plasma insulin response to fasting and refeeding in genetically obese hyperglycaemic (ob/ob) mice.
Br. J. Nutr. 51: 403-413, 1984.
46. Flatt, P.R.
Rapid screening of iodinated peptides for radioimmunoassay.

- Biochem. Soc. Trans. 12: 848-849, 1984.
47. Flatt, P.R., Bailey, C.J., Kwasowski, P., Page, T. and Marks, V.
Effects of exogenous and endogenous GIP in obese hyperglycaemic (ob/ob) mice.
Biochem. Soc. Trans. 12: 790-791, 1984.
 48. Moore, D.J., White, F.J., Flatt, P.R. and Parke, D.V.
Short term effects of bran supplementation on glucose and lipid metabolism in man.
Biochem. Soc. Trans. 12: 791-792, 1984.
 49. Flatt, P.R., Bailey, C.J., Kwasowski, P., Page, T. and Marks, V.
Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice.
J. Endocr. 101: 249-256, 1984.
 50. Flatt, P.R. and Swanston-Flatt, S.K.
Regulation of insulin secretion by human and rat islet cell tumours.
Biochem. Soc. Trans. 12: 1067-1068, 1984.
 51. Bailey, C.J. and Flatt, P.R.
Neurotensin modulation of the plasma insulin response to glucose in obese hyperglycaemic (ob/ob) mice.
Biochem. Soc. Trans. 12: 1092-1093, 1984.
 52. O'Hare, M.M.T., Shaw, C., Swanston-Flatt, S.K., Marcelli, M., Buchanan, K.D. and Flatt, P.R.
Influence of a transplantable insulinoma on the pancreatic status of insulin and pancreatic polypeptide in the rat.
Diabetologia 28: 157-160, 1985.
 53. Flatt, P.R. and Swanston-Flatt, S.K.
Role of calcium in defective insulin secretion from human and transplantable rat islet cell tumours.
Biomed. Biochim. Acta 44: 71-75, 1985.
 54. Sheppard, M.C., Bailey, C.J., Flatt, P.R., Swanston-Flatt, S.K. and Shennan, K.I.J.
Immunoreactive neurotensin in spontaneous syndromes of obesity and diabetes in mice.
Acta Endocrinologica 108: 532-536, 1985.
 55. Moore, D.J., White, F.J., Flatt, P.R. and Parke, D.V.
Beneficial short-term effects of unprocessed wheat bran on lipid and glucose metabolism in man.
Human Nutrition: Clinical Nutrition 39: 63-67, 1985.
 56. Flatt, P.R., Hampton, S.M., Bailey, C.J., Swanston-Flatt, S.K. and Marks, V.
Glucoregulation of plasma C-peptide in obese hyperglycaemic (ob/ob) mice.
Biochem. Soc. Trans. 13: 886-887, 1985.
 57. Berggren, P.-O. and Flatt, P.R.
Endogenous chromium in the tissues and body fluids of normal and genetically diabetic (db/db) mice.
Horm. Metab. Res. 3: 163-164, 1985.
 58. Berggren, P.-O. and Flatt, P.R.
Effects of trivalent chromium administration on endogenous chromium stores in lean and obese hyperglycaemic (ob/ob) mice.

- Nutr. Rep. Int. 31: 213-218, 1985.
59. Flatt, P.R., Bailey, C.J. Nield, S. and Swanston-Flatt, S.K.
Effect of meal-time on the glucose and insulin responses to conditioned feeding in lean and genetically obese hyperglycaemic (ob/ob) mice.
Nutr. Rep. Int. 31: 1341-1348, 1985.
 60. Bailey, C.J., Flatt, P.R. and Radley, N.S.
Effect of high fat and high carbohydrate cafeteria diets on the development of the obese hyperglycaemic (ob/ob) syndrome in mice.
Nutr. Res. 5: 1003-1010, 1985.
 61. Flatt, P.R., Bailey, C.J., Kwasowski, P., Swanston-Flatt, S.K. and Marks, V.
Glucoregulatory effects of cafeteria feeding and diet restriction in genetically obese hyperglycaemic (ob/ob) mice.
Nutr. Rep. Int. 32: 847-854, 1985.
 62. Flatt, P.R., Bone, A.J. and Bailey, C.J.
Islet cell surface antibodies in genetically obese hyperglycaemic (ob/ob) mice.
Biosci. Rep. 5: 715-720, 1985.
 63. Kwasowski, P., Flatt, P.R., Bailey, C.J. and Marks, V.
Effects of fatty acid chain length and saturation on gastric inhibitory polypeptide release in obese hyperglycaemic (ob/ob) mice.
Biosci. Rep. 5: 701-705, 1985.
 64. Flatt, P.R., Swanston-Flatt, S.K., Hampton, S.M., Bailey, C.J. and Marks, V.
Feedback inhibition of insulin release: a physiological role for proinsulin C-peptide?
Biochem. Soc. Trans. 14: 781-782, 1986.
 65. Bailey, C.J., Day, C., Bray, G.A., Lipson, L.G. and Flatt, P.R.
Role of the adrenal glands in the development of abnormal glucose and insulin homeostasis of genetically obese (ob/ob) mice.
Horm. Metab. Res. 18: 357-360, 1986.
 66. Flatt, P.R., Bailey, C.J., Cameron, A.M. and Gould, B.J.
Age effects on glycosylated blood proteins in lean and obese hyperglycaemic (ob/ob) mice.
Diabetes Res. 3: 241-243, 1986.
 67. Bailey, C.J., Thornburn, C.C. and Flatt, P.R.
Effects of ephedrine and atenolol on the development of obesity and diabetes in genetically obese hyperglycaemic (ob/ob) mice.
Gen. Pharmac. 17: 243-246, 1986.
 68. Flatt, P.R., Swanston-Flatt, S.K., Hampton, S.M., Bailey, C.J. and Marks, V.
Specific binding of the C-peptide of proinsulin to cultured B-cells from a transplantable rat islet cell tumour.
Biosci. Rep. 6: 193-199, 1986.
 69. Bailey, C.J., Flatt, P.R., Kwasowski, P., Powell, C.J. and Marks, V.
Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets.
Acta Endocrinologica 112: 224-229, 1986.
 70. Flatt, P.R., Bailey, C.J., Gray, C. and Swanston-Flatt, S.K.

- Metabolic effects of radiation induced rat insulinoma at pancreatic, hepatic and subscapular transplantation sites.
Comp. Biochem. Physiol. 85A: 183-186, 1986.
71. Bailey, C.J. and Flatt, P.R.
Anorectic effect of fenfluramine, cholecystokinin and neurotensin in genetically obese (ob/ob) mice.
Comp. Biochem. Physiol. 84A: 451-454, 1986.
 72. Conlon, J.M., Deacon, C.F., Bailey, C.J. and Flatt, P.R.
Effects of a transplantable insulinoma upon regulatory peptide concentrations in the gastrointestinal tract of the rat.
Diabetologia 29: 334-338, 1986.
 73. Flatt, P.R., Bailey, C.J. and Swanston-Flatt, S.K.
Hormonal modification of the growth and metabolic effects of a transplantable rat insulinoma.
Acta Endocrinologica 113: 82-87, 1986.
 74. Bailey, C.J., Flatt, P.R. and Ewan, C.
Anorectic effect of metformin in lean and genetically obese hyperglycaemic (ob/ob) mice.
Arch. Int. Pharm. Ther. 282: 233-239, 1986.
 75. Flatt, P.R., Tan, K.S., Bailey, C.J., Powell, C.J., Swanston-Flatt, S.K. and Marks, V.
Effects of transplantation and resection of a radiation-induced rat insulinoma on glucose homeostasis and the endocrine pancreas.
Br. J. Cancer 54: 685-692, 1986.
 76. Bailey, C.J., Flatt, P.R., Deacon, C.F., Shaw, C. and Conlon, J.M.
Substance P, neurokinin A, vasoactive intestinal polypeptide and gastrin-releasing peptide in the intestine and pancreas of spontaneously obese-diabetic mice.
Reg. Peptides 16: 339-348, 1986.
 77. Gould, B.J., Flatt, P.R., Kotecha, S., Collett, S. and Swanston-Flatt, S.K.
Measurement of glycosylated haemoglobins and glycosylated plasma proteins in animal models with diabetes or inappropriate hypoglycemia.
Horm. Metab. Res. 18: 795-799, 1986.
 78. Flatt, P.R., Tan, K.S., Swanston-Flatt, S.K., Webster, J.D. and Marks, V.
Metabolic effects and secretory properties of a radiation-induced transplantable rat insulinoma.
Comp. Biochem. Physiol. 87A: 175-181, 1987.
 79. Bailey, C.J., Flatt, P.R., Kwasowski, P. and Adams, M.
Gastric inhibitory polypeptide and the enteroinsular axis in streptozotocin diabetic mice.
Diabete Metab. 12: 351-354, 1987.
 80. Flatt, P.R., Swanston-Flatt, S.K., Tan, K.S. and Marks, V.
Effects of cytotoxic drugs and inhibitors of insulin secretion on a serially transplantable rat insulinoma and cultured rat insulinoma cells.
Gen. Pharmac. 18: 293-297, 1987.
 81. Flatt, P.R., Bailey, C.J., Hampton, S.M., Swanston-Flatt, S.K. and Marks, V.
Immunoreactive C-peptide in spontaneous syndromes of obesity and diabetes in mice.
Horm. Metab. Res. 19: 1-5, 1987.

82. Flatt, P.R., Bailey, C.J., Swanston-Flatt, S.K., Tan, K.S. and Marks, V.
Reversal of diabetes by syngeneic transplantation of a radiation induced rat insulinoma.
Diab. Res. Clin. Prac. 3: 63-69, 1987.
83. Bailey, C.J. and Flatt, P.R.
Glucagon-like peptide-1 and the enteroinsular axis in obese hyperglycaemic (ob/ob) mice.
Life Sciences 40: 521-525, 1987.
84. Flatt, P.R., Tan, K.S., Swanston-Flatt, S.K., Bailey, C.J. and Marks, V.
Defective diurnal changes of food intake, plasma glucose and insulin in rats with a transplantable islet cell tumour.
Horm. Res. 27: 47-52, 1987.
85. Bailey, C.J. and Flatt, P.R.
Increased responsiveness to glucoregulatory effects of opiates in obese-diabetic ob/ob mice.
Diabetologia 30: 33-37, 1987.
86. Flatt, P.R., Swanston-Flatt, S.K., Snell, K., Tan, K.S. and Marks, V.
Effects of diet-induced ketosis in rats with hypoglycaemia due to a serially transplantable insulinoma.
Diabete Metab. 13: 503-507, 1987.
87. Lenzen, S., Tiedge, M., Flatt, P.R., Bailey, C.J. and Panten, U.
Defective regulation of glucokinase in rat pancreatic islet cell tumours.
Acta. Endocrinologica 115: 514-520, 1987.
88. Conlon, J.M., Bailey, C.J. and Flatt, P.R.
Effect of a transplantable insulinoma on serotonin concentrations in the intestine of the rat.
Gut 28 (Suppl. 1): 213-216, 1987.
89. Bailey, C.J. and Flatt, P.R.
Insulin releasing effects of adrenocorticotropin (ACTH 1-39) and ACTH fragments (1-24 and 18-30) in lean and genetically obese hyperglycaemic (ob/ob) mice.
Int. J. Obes. 11: 109-115, 1987.
90. Flatt, P.R., DeSilva, M., Swanston-Flatt, S.K. and Marks, V.
Insulin secretion in vitro and in vivo from a transplantable NEDH rat insulinoma and derived clonal RINm5F cell line.
Diabetes Res. 6: 85-90, 1987.
91. Bailey, C.J. and Flatt, P.R.
Glucoregulatory effects of bombesin in lean and genetically obese hyperglycaemic (ob/ob) mice.
Comp. Biochem. Physiol. 88B: 359-362, 1987.
92. Flatt, P.R., Rorsman, P. and Swanston-Flatt, S.K.
Effects of cationic modification on superficial binding and intracellular ⁴⁵Ca uptake by decapsulated ob/ob mouse pancreatic islets.
Biomed. Res. 8: 153-159, 1987.
93. Flatt, P.R., Swanston-Flatt, S.K., Powell, C.J. and Marks, V.
Defective regulation of insulin release and transmembrane Ca²⁺ fluxes by human islet cell tumours.

- Br. J. Cancer. 56: 459-464, 1987.
94. Swanston-Flatt, S.K. and Flatt, P.R.
Acute and long-term effects of glucose on the function of transplantable rat insulinoma cells maintained in tissue culture.
Biomed. Res. 8: 215-223, 1987.
 95. Flatt, P.R. and Bailey, C.J.
Effect of cholecystokinin variants (CCK-8 and CCK-33) on insulin release and glucose tolerance in obese-diabetic (ob/ob) mice.
Med. Sci. Res. 15: 495-496, 1987.
 96. Flatt, P.R. and Best, L.
Abnormalities of inositol phospholipid metabolism in transplantable rat insulinoma cells maintained in tissue culture.
Med. Sci. Res. 15: 1419-1420, 1987.
 97. Flatt, P.R. and Bailey, C.J.
Effects of diet composition on the development of glucose homeostasis in mice.
Nutr. Rep. Int. 37: 281-287, 1988.
 98. Swanston-Flatt, S.K. and Flatt, P.R.
Effects of amino acids, hormones and drugs on insulin release and ⁴⁵Ca uptake by transplantable rat insulinoma cells maintained in tissue culture.
Gen. Pharmac. 19: 239-242, 1988.
 99. Swanston-Flatt, S.K. and Flatt, P.R.
Effects of cationic modification on ⁴⁵Ca uptake and insulin release by transplantable rat insulinoma cells maintained in tissue culture.
Gen. Pharmac. 19: 471-474, 1988.
 100. Flatt, P.R., Abrahamsson, H., Arkhammar, P., Berggren, P.-O., Rorsman, P. and Swanston-Flatt, S.K.
Measurements of membrane potential, transmembrane ⁴⁵Ca fluxes, cytoplasmic free Ca²⁺ concentration and insulin release by transplantable rat insulinoma cells maintained in tissue culture.
Br. J. Cancer 58: 22-29, 1988.
 101. Flatt, P.R., DeSilva, M., Swanston-Flatt, S.K., Powell, C.J. and Marks, V.
Tumour formation and insulin secretion by clonal RINm5F cells following repeated subcutaneous transplantation in NEDH rats.
J. Endocr. 118: 429-437, 1988.
 102. Ioannides, C., Bass, S.L., Ayrton, A.D., Trinick, J., Walker, R. and Flatt, P.R.
Streptozotocin-induced diabetes modulates the metabolic activation of chemical carcinogens.
Chem. Biol. Interact 68: 189-202, 1988.
 103. Barnett, C.R., Flatt, P.R. and Ioannides, C.
Role of ketone bodies in the diabetes-induced changes in hepatic mixed function oxidase activities.
Biochim. Biophys. Acta 967: 250-254, 1988.
 104. Flatt, P.R., Bass, S.L., Ayrton, A.D., Trinick, J. and Ioannides, C.
Metabolic activation of chemical carcinogens by hepatic preparations from streptozotocin-

- treated rats.
Diabetologia 32: 135-139, 1989.
105. Swanston-Flatt, S.K., Day, C., Flatt, P.R., Gould, B.J. and Bailey, C.J.
Glycaemic effects of traditional European plant treatments for diabetes.
Studies in normal and streptozotocin diabetic mice.
Diabetes Res. 10: 69-73, 1989.
 106. Flatt, P.R., Shibier, O., Ioannides, C. and Swanston-Flatt, S.K.
Studies on the chemical and immunological destruction of insulin-secreting islet cell tumours.
Exp. Clin. Endocr. 93: 193-202, 1989.
 107. Swanston-Flatt, S.K., Day, C., Bailey, C.J. and Flatt, P.R.
Evaluation of traditional plant treatments for diabetes: Studies in streptozotocin diabetic mice.
Acta diabet. lat. 26: 51-55, 1989.
 108. Flatt, P.R., Juntti-Berggren, L., Berggren, P.-O., Gould, B.J. and Swanston-Flatt, S.K.
Effects of dietary inorganic trivalent chromium (Cr^{3+}) on the development of glucose homeostasis in rats.
Diabete Metab. 15: 93-97, 1989.
 109. Flatt, P.R., Juntti-Berggren, L., Berggren, P.-O., Gould, B.J. and Swanston-Flatt, S.K.
Failure of Glucose Tolerance Factor - containing Brewer's yeast to ameliorate spontaneous diabetes in C57BL/KsJ db/db mice.
Diabetes Res. 10: 147-151, 1989.
 110. Bailey, C.J., Conlon, J.M. and Flatt, P.R.
Effect of ovarian hormones, pregnancy and lactation on somatostatin and substance P in the alimentary tract of mice.
J. Endocr. 122: 645-650, 1989.
 111. Flatt, P.R., Bailey, C.J., Kwasowski, P. and Swanston-Flatt, S.K.
Contribution of hyperphagia to the development of metabolic abnormalities in obese hyperglycaemic (ob/ob) mice.
Nutr. Rep. Int. 40: 1207-1215, 1989.
 112. Bailey, C.J., Wilkes, L., Flatt, P.R., Conlon, J.M. and Buchanan, K.D.
Effect of growth hormone releasing hormone on the secretion of islet hormones and glucose homeostasis in lean and genetically obese-diabetic (ob/ob) mice and normal rats.
J. Endocr. 123: 19-24, 1989.
 113. Flatt, P.R., Kwasowski, P. and Bailey, C.J.
Stimulation of gastric inhibitory polypeptide release in ob/ob mice by oral administration of sugars and their analogues.
J. Nutr. 119: 1300-1303, 1989.
 114. Flatt, P.R., Bailey, C.J., Kwasowski, P. and Swanston-Flatt, S.K.
Effects of diets rich in sucrose, coconut fat and safflowerseed oil on the development of the obese hyperglycaemic (ob/ob) syndrome in mice.
Diabetes Res. 13: 23-28, 1990.
 115. Flatt, P.R., Shibier, O., Hampton, S.M. and Marks, V.
Stimulatory effects of glucagon-like peptides on human insulinoma cells and insulin-releasing clonal RINm5F cells.

- Diabetes Res. 13: 55-59, 1990.
116. Flatt, P.R.
Defective regulation of insulin secretion in diabetes and insulinoma.
Biochem. Soc. Trans. 18: 124-127, 1990.
117. Barnett, C.R., Flatt, P.R. and Ioannides, C.
Hyperketonaemia markedly modulates the metabolic activation of chemical carcinogens.
Chem. Biol. Interact. 74: 281-289, 1990.
118. Ioannides, C., Ayrton, A.D., Keele, A., Lewis, D.F.V., Flatt, P.R. and Walker, R.
Mechanism of the *in vitro* antimutagenic action of retinol.
Mutagenesis 5: 257-262, 1990.
119. Barnett, C.R., Gibson, G.G., Wolf, C.R., Flatt, P.R. and Ioannides, C.
Induction of P450 III and P450 IV proteins in streptozotocin-induced diabetes.
Biochem. J. 268: 765-769, 1990.
120. Lenzen, S., Freytag, S., Panten, U., Flatt, P.R. and Bailey, C.J.
Alloxan inhibition of hexokinase from pancreatic islets and tumoral insulin-secreting cells.
Pharmacol. Toxicol. 66: 157-162, 1990.
121. Swanston-Flatt, S.K., Day, C., Bailey, C.J. and Flatt, P.R.
Traditional plant treatment for diabetes: Studies in normal and streptozotocin diabetic mice.
Diabetologia 33: 462-464, 1990.
122. Barnett, C.R., Flatt, P.R. and Ioannides, C.
Induction of hepatic microsomal P-450 I and IIB proteins by hyperketonaemia.
Biochem. Pharmacol. 40: 393-397, 1990.
123. Bailey, C.J. and Flatt, P.R.
Adrenoceptor-mediated control of glucose homeostasis in obese hyperglycaemic (ob/ob) mice.
Diabetes Res. 14: 87-91, 1990.
124. Flatt, P.R., Kwasowski, P., Howland, R.J. and Bailey, C.J.
Gastric inhibitory polypeptide and insulin responses to orally administered amino acids in genetically obese hyperglycaemic (ob/ob) mice.
J. Nutr. 121: 1123-1128, 1991.
125. Flatt, P.R., Bailey, C.J., Swanston-Flatt, S.K., McGregor, G.P. and Conlon, J.M.
Substance P, neurokinin A and calcitonin gene-related peptide during the development of the rat gastrointestinal tract.
Reg. Peptides 33: 313-320, 1991.
126. Flatt, P.R., Bailey, C.J. and Conlon, J.M.
Somatostatin, gastrin-releasing peptide and gastrin in the stomach of rats with streptozotocin-induced diabetes and insulinoma.
J. Nutr. 121: 1414-1417, 1991.
127. Williams, G., Cardoso, H., Lee, Y.C., Ghatei, M.A., Flatt, P.R., Bailey, C.J. and Bloom, S.R.
Reduced hypothalamic neurotensin concentrations in genetically obese diabetic (ob/ob) mouse: Possible relationship to obesity.
Metabolism 40: 1112-1116, 1991.

128. Ponter, A.A., Salter, D.N., Morgan, L.M. and Flatt, P.R.
The effect of energy source and feeding level on the hormones of the entero-insular axis and plasma glucose in the growing pig.
Br. J. Nutr. 66: 187-197; 1991.
129. Barnett, C.R., Flatt, P.R. and Ioannides, C.
Hyperinsulinaemia causes a preferential increase in hepatic P450 IA2 activity.
Biochem. Pharmacol. 43: 1255-1261; 1992.
130. Barnett, C.R., Flatt, P.R. and Ioannides, C.
Cytochrome P450-dependent mixed function oxidase and glutathione-S-transferase activity in spontaneous obesity-diabetes.
Biochem. Pharmacol. 43: 1868-1871; 1992.
131. Barnett, C.R., Petrides, L., Wilson, J., Flatt, P.R. and Ioannides, C.
Induction of the rat hepatic mixed function oxidases by acetone and other physiological ketones: Their role in the diabetes-induced cytochrome P450 proteins.
Xenobiotica 22: 1441-1450; 1992.
132. Barnett, C.R., Rudd, S., Flatt, P.R. and Ioannides, C.
Sex differences in the diabetes-induced modulation of rat hepatic cytochrome P450 proteins.
Biochem. Pharmacol. 45: 313-319; 1993.
133. Flatt, P.R., Barnett, C.R. and Swanston-Flatt, S.K.
Mechanisms of pancreatic B-cell dysfunction and glucose toxicity in non-insulin-dependent diabetes.
Biochem. Soc. Trans. 22: 18-23, 1994.
134. McClenaghan, N.H., Yoon, T.W., Barnett, C.R., Wilson, A.M., Abdelwahab, Y.H.A., Swanston-Flatt, S.K., Ah-Sing, E. and Flatt, P.R.
Effect of nutrients on insulin secretion from a novel pancreatic B-cell line produced by electrofusion.
Biochem. Soc. Trans. 22: 237S, 1994.
135. O'Harte, F.P.M., Boyd, A., Abdelwahab, Y.H.A., Barnett, C.R. and Flatt, P.R.
Characterisation of the glycation of human insulin by reversed-phase HPLC.
Biochem. Soc. Trans. 22: 239S, 1994.
136. Abdelwahab, Y.H.A., O'Harte, F.P.M., Barnett, C.R. and Flatt, P.R.
Studies of the effect of glycation of insulin on biological action in isolated mouse diaphragm muscle.
Biochem. Soc. Trans. 22: 238S, 1994.
137. Barnett, C.R., Flatt, P.R. and Ioannides, C.
Modulation of the rat hepatic cytochrome P-450 composition by long-term streptozotocin-induced insulin-dependent diabetes.
J. Biochem. Toxicol. 9: 63-69, 1994.
138. Flatt, P.R., Shibier, O., Szechowka, J. and Berggren, P.-O.
New perspectives on the actions of sulphonylureas and hyperglycaemic sulphonamides on the pancreatic B-cell.
Diabetes Metab. 20: 157-162, 1994.
139. McDermott, B.M., Flatt, P.R. and Strain, J.J.
The effects of copper deficiency and experimental diabetes on tissue antioxidant enzyme

- levels in rats.
Annals Nutr. Metab., 38: 263-269; 1994.
140. Abdelwahab, Y.H.A., O'Harte, F.P.M., Barnett, C.R. and Flatt, P.R.
Studies of the effect of glycation of insulin on biological action in isolated mouse diaphragm muscle.
Biochem. Soc. Trans., 22: 238S, 1994.
 141. Irazar, A., Barnett, C.R., Flatt, P.R., Ioannides, C.
Defective expression of cytochrome P450 proteins in liver of the genetically obese Zucker rat.
Eur. J. Pharmacol. 293: 385-393; 1995.
 142. McDermott, B.M., Strain, J.J. and Flatt, P.R.
Effects of dietary carbohydrate intake on antioxidant enzyme activity and copper status in the copper deficient streptozotocin (STZ) diabetic rat.
J. Nutr. Biochem. 6: 638-643; 1995
 143. McClenaghan, N.H., Barnett, C.R., Ah-Sing, E., Swanston-Flatt, S.K. and Flatt, P.R.
Secretory properties of clonal insulin-secreting BRIN-BG5 cells produced by electrofusion.
Biochem. Soc. Trans. 24: 101S; 1996.
 144. Flatt, P.R.
Pancreatic B-cells as mediators of metabolic effects of regulatory peptides.
Biochem. Soc. Trans., 24: 570-575; 1996.
 145. Rasschaert, J., Flatt, P.R., Barnett, C.R., McClenaghan, N.H. and Malaisse, W.J.
D-glucose metabolism in BRIN-BD11 cells.
Biochem. Molec. Med. 57: 97-105; 1996.
 146. McClenaghan, N.H., Barnett, C.R., O'Harte, F.P.M., Swanston-Flatt, S.K., Ah-Sing, E. and Flatt, P.R.
Characteristics of BRIN-BG5 and BRIN-BG7, two novel glucose-responsive insulin-secreting cell lines produced by electrofusion.
J. Endocr., 148: 409-417; 1996.
 147. Eliasson, L., Renstrom, E., Ammala, C., Berggren, P.-O., Bertorello, A.M., Bokvist, K., Chibalin, A., Deeney, J.T., Flatt, P.R., Gabel, J., Gromada, J., Larsson, O., Lindstrom, P., Rhodes, C.J. and Rorsman, P.
PKC-Dependent stimulation of exocytosis by sulfonylureas in pancreatic B-cells.
Science 271: 813-815; 1996.
 148. McClenaghan, N.H., Gray, A.M., Barnett, C.R. and Flatt, P.R.
Hexose recognition by insulin-secreting BRIN-BD11 cells.
Biochem. Biophys. Res. Comm. 223: 724-728; 1996.
 149. McClenaghan, N.H., Barnett, C.R., Ah-Sing, E., Abdel-Wahab, Y.H.A., O'Harte, F.P.M., Yoon, T.-W., Swanston-Flatt, S.K. and Flatt, P.R.
Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion.
Diabetes 45: 1132-1140; 1996.
 150. Abdel-Wahab, Y.H.A., O'Harte, F.P.M., Ratcliff, H., McClenaghan, N.H., Barnett, C.R. and Flatt, P.R.
Glycation of insulin in the islets of Langerhans of normal and diabetic animals.
Diabetes, 45: 1489-1496; 1996.

151. McClenaghan, N.H., Barnett, C.R., O'Harte, F.P.M. and Flatt, P.R.
Mechanisms of amino acid induced insulin secretion from the glucose-responsive BRIN-BD11 pancreatic B-cell line.
J. Endocr., 151: 349-357; 1996.
152. O'Harte, F.P.M., Hojrup, P., Barnett, C.R. and Flatt, P.R.
Identification of the site of glycation of human insulin.
Peptides, 17: 1323-1330; 1996.
153. Clarke, J., Snelling, J., Ioannides, C., Flatt, P.R. and Barnett, C.R.
Effect of vitamin C supplementation on hepatic cytochrome P450 mixed-function oxidase activity in streptozotocin-diabetic rats.
Toxicol. Letters 89: 249-256; 1996.
154. Rasschaert, J., Flatt, P.R., McClenaghan, N.H. and Malaisse, W.J.
Amino acid oxidation in BRIN-BD11 islet cells.
Med. Sci. Res. 24: 691-692; 1996.
155. Clarke, J., Flatt, P.R. and Barnett, C.R.
Molecular toxicology of pancreatic B-cell dysfunction and destruction.
Irish Scientist 4: 54; 1996.
156. McClenaghan, N.H., Barnett, C.R. and Flatt, P.R.
Production of novel insulin-secreting pancreatic B-cell lines.
Irish Scientist 4: 54; 1996.
157. Clarke, J.C., Flatt, P.R. and Barnett, C.R.
The role of cytochrome P450 in altered pancreatic B-cell responsiveness.
Biochem. Soc. Trans. 25: 122S; 1997.
158. Abdel-Wahab, Y.H.A., O'Harte, F.P.M., Barnett, C.R. and Flatt, P.R.
Glycation of insulin in a cultured insulin-secreting cell line.
Biochem. Soc. Trans. 25: 128S; 1997.
159. Clarke, J.C., Coulter, J., Flatt, P.R. and Barnett, C.R.
Islet antioxidant and second-phase enzyme levels following CYP1A, CYP2E, CYP2B and CYP4A induction.
Biochem. Soc. Trans. 25: 133S; 1997.
160. Abdel-Wahab, Y.H.A., O'Harte, F.P.M., Barnett, C.R. and Flatt, P.R.
Characterisation of insulin glycation in insulin-secreting cells maintained in tissue culture.
J. Endocr. 152: 59-67; 1997.
161. Bailey, C.J., Day, C., Knapper, J.M.E., Turner, S.L. and Flatt, P.R.
Antihyperglycaemic effect of saccharin in diabetic ob/ob mice.
Br. J. Pharmacol. 120: 74-78; 1997.
162. Gray, A.M. and Flatt, P.R.
Pancreatic and extrapancreatic effects of the traditional antidiabetic plant, *Medicago sativa* (alfalfa).
Br. J. Nutr. 78: 325-334; 1997.
163. Clarke, J., Flatt, P.R. and Barnett, C.R.
Cytochrome P450 CYP1A - like proteins expressed in the islets of Langerhans and altered

- pancreatic B-cell secretory responsiveness.
Br. J. Pharmacol. 121: 389-394; 1997.
164. McClenaghan, N.H., Barnett, C.R. and Flatt, P.R.
Mechanisms of action of cationic amino acids on insulin-secreting BRIN-BD11 cells.
Biochem. Soc. Trans. 25: 144S; 1997.
 165. O'Harte, F.P.M., Penney, A.C. and Flatt, P.R.
Glycation of insulin by phosphorylated and non-phosphorylated reducing sugars.
Biochem. Soc. Trans. 25: 150S; 1997.
 166. McDonagh, M., Ali, L., Kahn, A., Flatt, P.R., Barnett, Y.A. and Barnett, C.R.
Antioxidant status, oxidative stress and DNA damage in the aetiology of malnutrition-related diabetes mellitus.
Biochem. Soc. Trans. 25: 146S; 1997.
 167. O'Harte, F.P.M., Gray, A.M., Abdel-Wahab, Y.H.A. and Flatt, P.R.
Effects of non-glycated and glycated glucagon-like peptide-1 (7-36) amide on glucose metabolism in isolated mouse abdominal muscle.
Peptides 18: 1327-1333; 1997.
 168. Abdel-Wahab, Y.H.A., Boyd, A.C., Barnett, C.R., O'Harte, F.P.M. and Flatt, P.R.
Non-enzymic glycosylation of insulin results in reduced biological activity in mice.
Acta Diabetol. 34: 265-270; 1997.
 169. O'Harte, F.P.M., Gray, A.M. and Flatt, P.R.
Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle.
J. Endocr. 156: 237-243; 1998.
 170. Ding, X.-Y., Flatt, P.R. Permert, J. and Adrian, T.E.
Pancreatic cancer cells selectively stimulate co-cultured islet B-cells to secrete amylin.
Gastroenterology 114: 130-138; 1998.
 171. McClenaghan, N.H., Flatt, P.R. and Bailey, C.J.
Insulin-releasing action of the novel antidiabetic agent BTS 67582.
Br. J. Pharmacol. 123: 400-404; 1998.
 172. McClenaghan, N.H., Elsner, M., Tiedge, M. and Lenzen, S.
Molecular characterisation of the glucose-sensing mechanism in the clonal insulin-secreting BRIN-BD11 cell line.
Biochem. Biophys. Res. Comm. 242: 262-266; 1998.
 173. Gray, A.M. and Flatt, P.R.
Insulin-releasing and insulin-like activity of *Agaricus campestris* (mushroom).
J. Endocr. 157: 259-266; 1998.
 174. Gray, A.M. and Flatt, P.R.
Actions of the traditional antidiabetic plant, *Agrimony eupatoria* (agrimony): Effects on hyperglycaemia, cellular glucose metabolism and insulin secretion.
Br. J. Nutr. 80: 109-114; 1998.
 175. O'Harte, F.P.M., Mooney, M., Kelly, C.M.N. and Flatt, P.R.
Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation.

- Diabetes 47: 1619-1624; 1998.
176. O'Harte, F.P.M., Abdel-Wahab, Y.H.A., Conlon, J.M. and Flatt, P.R.
Glycation of glucagon-like peptide-1 (7-36) amide: Characterisation and impaired action on rat insulin secreting cells.
Diabetologia 41 1187-1193; 1998.
177. McClenaghan, N.H., Barnett, C.R. and Flatt, P.R.
Na⁺ co-transport by metabolizable and non-metabolizable amino acids stimulates a glucose-regulated insulin-sescretory response.
Biochem. Biophys. Res. Comm. 249: 299-303; 1998.
178. O'Harte, F.P.M., Abdel-Wahab, Y.H.A., Conlon, J.M. and Flatt, P.R.
Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells.
Biochim. Biophys. Acta 1425: 319-327; 1998.
179. Gray, A.M. and Flatt, P.R.
Antihyperglycemic actions of Eucalyptus globulus (eucalyptus) are associated with pancreatic and extrapancreatic effects.
J. Nutr. 128: 2319-2323; 1998.
180. O'Harte, F.P.M., Abdel-Wahab, Y.H.A., Conlon, J.M. and Flatt, P.R.
Glycated IAPP shows reduced inhibitory action on insulin secretion.
Biochem. Soc. Trans. 26: S6; 1998.
181. Gray, A.M. and Flatt, P.R.
Insulin-releasing activity of the traditional anti-diabetic plant Viscum album (mistletoe).
J. Endocrinol., 160: 409-414; 1999.
182. McClenaghan, HN.H. and Flatt, P.R.
Glucose and non-glucidic nutrients exert permissive effects on 2-keto acid regulation of pancreatic B-cell function.
Biochim. Biophys. Acta 1426: 110-118; 1999.
183. Gray, A.M. and Flatt, P.R.
Insulin-releasing and insulin-like activity of the traditional antidiabetic plant Coriandrum sativum (coriander).
Br. J. Nutr. 81: 203-209; 1999.
184. O'Harte, F.P.M., Mooney, M.H. and Flatt, P.R.
N-terminally glycated gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.
Diabetes, 48: 758-765; 1999.
185. Abdel-Wahab, Y.H.A., O'Harte, F.P.M., Mooney, M., Conlon, J.M. and Flatt, P.R.
Glycation of CCK-8 abolishes its insulinotropic action on clonal pancreatic B-cells.
Biochim. Biophys. Acta, 1452: 60-67; 1999.
186. Salgado, A.P., Pereira, F.C., Seica, R.M., Fernandez, A.P., Flatt, P.R., Santos, R.M., Rosario, L.M. and Ramasamy, R.
Modulation of glucose-induced insulin secretion by cytosolic redox state in clonal B-cells.
Mol. Cell Endocrinol, 154: 79-88; 1999.

187. Chapman, J.C., McClenaghan, N.H., Cosgrove, K.E., Hashmi, M.N., Shepherd, R., Giesberts, A.N., White, S., Ammala, C., Flatt, P.R. and Dunne, M.J.
ATP-sensitive potassium channels and efaroxan-induced insulin release in the electrofusion-derived BRIN-BD11 beta-cell line.
Diabetes 48: 2349-2357; 1999.
188. Conroy, S., Abdel-Wahab, Y.H.A., Caraher, E., Byrne, P.M., Murphy, E., Nolan, J., Flatt, P.R. and Newsholme, P.
Evidence for complement-dependent inhibition of insulin secretion from clonal B-cells incubated in the presence of newly diagnosed IDDM patient sera.
J. Endocrinol., 164: 139-147; 2000.
189. Gray, A.M., Abdel-Wahab, Y.H.A. and Flatt, P.R.
Insulin-like and insulin-releasing actions of the traditional antidiabetic plant *Sambus nigra* (elder).
J. Nutr. 130: 15-20; 2000.
190. McClenaghan, N.H. and Flatt, P.R.
Metabolic and K⁺-ATP channel independent actions of keto acid initiators of insulin secretion.
Pancreas, 20: 38-46; 2000.
191. O'Harte, F.P.M., Mooney, M.H., Lawlor, A. and Flatt, P.R.
N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo.
Biochim. Biophys. Acta 1471: 13-22; 2000.
192. Ahmad, M., Abdel-Wahab, Y.H.A., Tate, R., Flatt, P.R., Pyne, N.J. and Furman, B.L.
Effect of type-selective inhibitors on cyclic nucleotide phosphodiesterase activity and insulin secretion in the clonal insulin secreting cell line BRIN-BD11.
Br. J. Pharmacol. 129: 1228-1234; 2000.
193. Saldago, A.P., Santos, R.M., Fernandez, A.P., Tome, A.R., Flatt, P.R. and Rosario, L.M.
Glucose-mediated Ca²⁺ signalling in clonal insulin-secreting BRIN-BD11 cells: Evidence for mixed model of cellular activation.
Int. J. Biochem. Cell Biol. 32: 557-569; 2000.
194. McClenaghan, N.H., Ball, A.J. and Flatt, P.R.
Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide.
Br. J. Pharmacol. 130: 478-484; 2000.
195. O'Harte, F.P.M., Mooney, M.H., Kelly, C.M.N. and Flatt, P.R.
Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide.
J. Endocrinol. 165: 639-648; 2000.
196. Boyd, A.C., Abdel-Wahab, Y.H.A., McKillop, A.M., McNulty, H., Barnett, C.R., O'Harte, F.P.M. and Flatt, P.R.
Impaired ability of glycated insulin to regulate plasma glucose and stimulate glucose transport and metabolism in mouse abdominal muscle..
Biochem. Biophys. Acta, 1519: 128-134; 2000.
197. Ball, A.J., McCluskey, J.T., Flatt, P.R. and McClenaghan, N.H.
Drug-induced desensitisation of insulinotropic actions of sulphonylureas.

- Biochem. Biophys. Res. Comm. 271: 234-239; 2000.
198. Hamid, M., McCluskey, J.T., McClenaghan, N.H. and Flatt, P.R.
Culture and function of electrofusion-derived clonal insulin-secreting cells immobilised on solid and macroporous microcarrier beads.
Biosci. Rep., 20: 167-176, 2000.
 199. Ball, A.J., Flatt, P.R. and McClenaghan, N.H.
Stimulation of insulin secretion by the imidazoline derivatives KU14R and RX801080.
Pharmacol. Res., 42: 575-579; 2000.
 200. Ball, A.J., Flatt, P.R. and McClenaghan, N.H.
Desensitisation of sulphonylurea- and nutrient-induced insulin secretion following prolonged treatment with glibenclamide.
Eur. J. Pharmacol., 408: 327-333; 2000.
 201. O'Harte, F.P.M., Boyd, A.C., McKillop, A.M., Abdel-Wahab, Y.H.A., McNulty, H., Barnett, C.R., Conlon, J.M., Hojrup, P. and Flatt, P.R.
Structure, antihyperglycaemic activity and cellular actions of a novel diglycated human insulin.
Peptides, 21: 1519-1526, 2000.
 202. McKillop, A.M., Mooney, M.H., Boyd, A.C., Flatt, P.R. and O'Harte, F.P.M.
Production and characterization of specific antibodies for evaluation of glycated insulin in plasma and biological tissues.
J. Endocrinol, 167: 153-163; 2000.
 203. Ahmad, M., Flatt, P.R., Furman, B.L. and Pyne, N.J.
The type III cyclic AMP phosphodiesterase, phosphoinositide 3-kinase and p42/p44 mitogen-activated protein kinase protect clonal insulin-secreting cells from apoptosis.
Cell Signalling, 12: 541-548; 2000.
 204. McClenaghan, N.H., Ball, A. and Flatt, P.R.
Prolonged exposure to tolbutamide specifically desensitises sulphonylurea but not imidazoline-induced insulin release.
Biochem. Pharmacol, 61: 527-536; 2001.
 205. O'Harte, F.P.M., Mooney, M.H., Kelly, C.M.N., McKillop, A.M. and Flatt, P.R.
Degradation and glycaemic effects of His⁷-glucitol glucagon-like peptide-1 (7-36)amide in obese diabetic ob/ob mice.
Reg. Peptides, 96: 95-104; 2001.
 206. Hamid, M., McCluskey, J.T., McClenaghan, N.H. and Flatt, P.R.
Comparative functional study of clonal insulin-secreting cells cultured in five commercially available tissue culture media.
Cell Transplant, 10: 153-159; 2001.
 207. Hamid, M., McCluskey, J.T., McClenaghan, N.H. and Flatt, P.R.
Functional examination of microencapsulated clonal insulin-secreting beta-cells
Cell Biol. Int. 25: 553-556; 2001.
 208. Picton, S.F., Flatt, P.R. and McClenaghan, N.H.
Differential acute and long-term actions of succinic acid monomethyl ester exposure on insulin secreting cells.
Int. J. Exper. Diab. Res., 2: 19-27; 2001.

209. Davies, E., Abdel-Wahab, Y.H.A., Flatt, P.R. and Bailey, C.J.
Functional enhancement of electrofusion-derived BRIN-BD11 cells insulin-secreting cells after implantation into diabetic mice.
Int. J. Exper. Diab. Res., 2: 29-36; 2001.
210. McKillop, A.M., Mooney, M.H., McCluskey, J.T., Abdel-Wahab, Y.H.A., Harriott, P., O'Harte, F.P.M. and Flatt, P.R.
Evaluation of glycated insulin in pancreas and circulation of diabetic animal models using immunocytochemistry and a novel and specific radioimmunoassay.
Biochem. Biophys. Res. Commun. 286: 524-528; 2001.
211. Mooney, M.H., Abdel-Wahab, Y.H.A., Morgan, L.M., O'Harte, F.P.M. and Flatt, P.R.
Detection of glycated gastric inhibitory polypeptide within the intestines of diabetic-obese (ob/ob) mice.
Endocrine, 16: 167-171; 2001.
212. Abdel-Wahab, Y.H.A., O'Harte, F.P.M., Barnett, C.R. and Flatt, P.R.
Effects of vitamin C supplementation on insulin glycation and glucose homeostasis in obese hyperglycaemic (ob/ob) mice.
Metabolism, 51: 514-517; 2002.
213. Furman, B.L. and Flatt, P.R.
Report of the 11th EASD Islet Group meeting. Glasgow, UK, 13-15 September 2001.
Diabetologia. 45: R26-R29; 2002.
214. Conroy, S.J., Green, I.C., Byrne, P.M., Nolan, J., Flatt, P.R. and Newsholme, P.
Evidence for a sustained increase in clonal beta cell intracellular Ca²⁺ levels after incubation in the presence of newly diagnosed type-1 diabetic patient sera. Possible role in serum-induced inhibition of insulin secretion.
J. Endocrinol., 173: 53-62; 2002.
215. Mooney, M.H., Abdel-Wahab, Y.H.A., McKillop, A.M., O'Harte, F.P.M. and Flatt, P.R.
Evaluation of glycated glucagon-like peptide-1(7-36)amide in intestinal tissue of normal and diabetic animal models.
Biochem. Biophys. Acta, 1569: 75-80; 2002.
216. Van Eylen F., Horta, O.D., Barez, A., Kamagate A., Flatt, P.R., Macianskiene, R., Mubagwa, K. and Herchuelz, A.
Overexpression of the Na/Ca exchanger shapes stimulus-induced cytosolic Ca²⁺ oscillations in insulin-producing BRIN-BD11 cells.
Diabetes 51: 366-375; 2002.
217. Gault, V.A., O'Harte, F.P.M., Harriott, P. and Flatt, P.R.
Characterisation of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide.
Biochem. Biophys. Res. Comm. 290: 1420-1426; 2002.
218. Miguel, J.C., Abdel-Wahab, Y.H.A., Mathias, P.C. and Flatt, P.R.
Muscarinic receptor subtypes mediate stimulatory and paradoxical inhibitory effects on an insulin-secreting beta cell line.
Biochim. Biophys. Acta, 1569: 45-50; 2002.
219. O'Harte, F.P.M., Gault, V.A., Parker, J.C., Harriott, P., Mooney, M.H., Bailey, C.J. and Flatt, P.R.

- Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. *Diabetologia*, 45: 1281-1291; 2002.
220. Brennan, L., Shine, A., Hewage, C., Malthouse, J.P.G., Brindle, K.M., McClenaghan, N.H., Flatt, P.R. and Newsholme, P.
A NMR based demonstration of substantial oxidative L-alanine metabolism and L-alanine enhanced glucose metabolism in a clonal pancreatic beta cell line – Metabolism of L-alanine is important to the regulation of insulin secretion.
Diabetes, 51: 1714-1721; 2002.
 221. Hamid, M., McCluskey, J.T., McClenaghan, N.H. and Flatt, P.R.
Comparison of the secretory properties of four insulin-secreting cell lines.
Endocrine Res., 28: 35-47; 2002.
 222. Gault, V.A., Flatt, P.R., Bailey, C.J., Harriott, P., Greer, B., Mooney, M.H. and O'Harte, F.P.M.
Enhanced cyclic AMP generation and insulin-releasing potency of two novel Tyr¹-modified enzyme resistant forms of GIP, is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.
Biochem. J., 367: 913-920; 2002.
 223. McKillop, A.M., Abdel-Wahab, Y.H.A., Mooney, M.H., O'Harte, F.P.M. and Flatt, P.R.
Secretion of glycated insulin from pancreatic beta cells in diabetes represents a novel aspect of beta cell dysfunction and glucose toxicity.
Diabetes Metab., 28: 3S61-3S69; 2002.
 224. Gault, V.A., Harriott, P., Flatt, P.R. and O'Harte, F.P.M.
Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulintropic peptide.
Biosci. Rep., 22: 523-528; 2002.
 225. Picton, S.F., McCluskey, J.T., Flatt, P.R. and McClenaghan, N.H.
Effects of cytotoxic agents on functional integrity and antioxidant enzymes in clonal beta cells.
Diabetes Metab., 28: 3S70-3S77; 2002.
 226. Gault, V.A., Parker, J.C., Harriott, P., Flatt, P.R. and O'Harte, F.P.M.
Evidence that the major degradation product of glucose-dependent insulintropic polypeptide (GIP), GIP(3-42), is a GIP receptor antagonist in vivo.
J. Endocrinol., 175: 525-533; 2002.
 227. Gault, V.A., Flatt, P.R., Bailey, C.J., Harriott, P., Greer, B., Mooney, M.H. and O'Harte, F.P.M.
Improved biological activity of Gly² and Ser² substituted analogs of glucose-dependent insulintropic polypeptide.
J. Endocrinol., 176: 133-141; 2003.
 228. Miguel, J.C., Abdel-Wahab, Y.H.A., Green, B.D., Mathias, P.C. and Flatt, P.R.
Cooperative enhancement of insulintropic action of GLP-1 by acetylcholine uncovers paradoxical inhibitory effect of beta cell muscarinic receptor activation on adenylate cyclase activity.
Biochem. Pharmacol., 65: 283-292; 2003.
 229. Gault, V.A., Irwin, N., Harriott, P., Flatt, P.R. and O'Harte, F.P.M.

- DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser²-Asp¹³)GIP.
Cell Biol. International, 27: 41-46; 2003.
230. Hunter, S.J., Boyd, A.C., O'Harte, F.P.M., McKillop, A.M., Wiggan, M.I., Ennis, C.N., Gamble, R., Sheridan, B., Barnett, C.R., McNulty, H., Bell, P.M. and Flatt, P.R.
Demonstration of glycated insulin in human diabetic plasma and decreased biological activity by euglycemic clamp technique in man.
Diabetes, 52: 492-498; 2003.
 231. Gallagher, A.M., Duffy, G., Flatt, P.R. and Abdel-Wahab, Y.H.A.
The effects of traditional antidiabetic plants on in vitro glucose diffusion.
Nutr. Res. 113: 413-424; 2003.
 232. McKillop, A.M., Meade A., Flatt, P.R. and O'Harte, F.P.M.
Evaluation of the site(s) of glycation in human proinsulin by ion-trap LCQ-electrospray ionization mass spectrometry.
Reg. Peptides 113: 1-8; 2003.
 233. Lindsay, J.R., McKillop, A.M., Mooney, M.H., Flatt, P.R., Bell, P.M. and O'Harte, F.P.M.
Meal-induced twenty-four hour profile of circulating insulin in type 2 diabetic subjects.
Metabolism 52: 631-635; 2003.
 234. Lindsay, J.R., McKillop, A.M., Mooney, M.H., O'Harte, F.P.M., Bell, P.M. and Flatt, P.R.
Demonstration of elevated concentrations of circulating glycated insulin in human type 2 diabetes using a novel and specific radioimmunoassay.
Diabetologia 46: 475-478; 2003.
 235. Gault, V.A., O'Harte, F.P.M., Harriott, P. and Flatt, P.R.
Degradation, cyclic AMP production, insulin secretion and glycaemic effects of two novel N-terminal Ala²-substituted analogues of GIP with preserved biological activity in vivo.
Metabolism 52: 679-687; 2003.
 236. Gault, V.A., O'Harte, F.P.M., Harriott, P., Mooney, M.H., Green, B.D. and Flatt, P.R.
Effects of the novel (Pro³)GIP antagonist and exendin(9-39) on GIP- and GLP-1-induced cAMP generation, insulin secretion and postprandial insulin release in obese diabetic ob/ob mice: Evidence that GIP is the major physiological incretin.
Diabetologia, 46: 222-2320; 2003.
 237. Brennan, L., Corless, M., Hewage, C., Malthouse, J.P.G., McClenaghan, N.H., Flatt, P.R. and Newsholme, P.
¹³C NMR Analysis reveals a link between L-glutamine metabolism, L-glutamate concentration and γ -glutamyl cycle activity in a clonal pancreatic beta cell line.
Diabetologia 46: 1512-1521; 2003.
 238. Lindsay, J.R., McKillop, A.M., Mooney, M.H., O'Harte, F.P.M., Flatt, P.R. and Bell, P.M.
Nateglinide effects on the secretion of glycated insulin and glucose tolerance in Type 2 diabetes.
Diabetes. Res. Clin. Pract., 61: 167-173; 2003.
 239. Dixon, G., Nolan, J., McClenaghan, N.H., Flatt, P.R. and Newsholme, P.
A comparative study of nutrient consumption by rat islet cells and the clonal beta-cell line BRIN-BD11 – the functional significance of L-alanine.
J. Endocrinol. 179: 447-454; 2003.

240. Green, B.D., Mooney, M.H., Gault, V.A., Bailey, C.J., Irwin, N., Harriott, P., Greer, B., Flatt, P.R. and O'Harte, F.P.M. Metabolic stability, receptor binding, cyclic AMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal (Glu⁹)-substituted analogues of glucagon-like peptide-1. *Biological Chemistry* 384: 1543-1551; 2003.
241. Green, B.D., Mooney, M.H., Gault, V.A., Bailey, C.J., Irwin, N., Harriott, P., Greer, B., Flatt, P.R. and O'Harte, F.P.M. Novel DPP IV resistant analogues of GLP-1 with potent insulinotropic activity in vitro conferring improved glucose-lowering action in vivo. *J. Mol. Endocrinol.*, 31: 529-540; 2003.
242. Marenah, L., Orr, D.F., McClean, S., Flatt, P.R., Shaw, C. and Abdel-Wahab, Y.H.A. Isolation and characterisation of a novel class of insulinotropic peptides in the skin of the frog *Agalychnis litodryas*. *Reg. Peptides*, 120: 33-38; 2004.
243. Lees Murdock, D.J., Clarke, J., Flatt, P.R., Barnett, Y.A. and Barnett, C.R. Role of CYP2E1 in ketone-stimulated insulin release in pancreatic B-cells. *Biochem. Pharmacol.*, 67: 875-884; 2004.
244. Marenah, L., McClean, S., Orr, D.F., Flatt, P.R., Shaw, C. and Abdel-Wahab, Y.H.A. Novel insulin-releasing peptides in the skin of *Phyllomedusa trinitatis* frog include 28 amino acid peptide from dermaseptin BIV precursor *Pancreas*, 29: 110-115; 2004.
245. Green, B.D., Mooney, M.H., Gault, V.A., Bailey, C.J., Irwin, N., Harriott, P., Greer, B., Flatt, P.R. and O'Harte, F.P.M. N-terminal His⁷-modification of GLP-1 generates DPP IV-stable analogues with potent antihyperglycaemic activity. *J. Endocrinol.*, 180: 379-388; 2004.
246. Miguel J.C., Abdel-Wahab, Y.H.A., Mathias, P.C.F. and Flatt, P.R. Time-correlation between membrane depolarization and intracellular calcium in insulin-secreting BRIN-BD11 cells: Studies using FLIPR. *Cell Calcium* 36: 43-50; 2004.
247. Green, B.D., Mooney, M.H., Gault, V.A., Bailey, C.J., Irwin, N., Harriott, P., Greer, B., Flatt, P.R. and O'Harte, F.P.M. Lys⁹ for Glu⁹ substitution in glucagon-like peptide-1(7-36)amide (GLP-1) confers DPP IV resistance with cellular and metabolic actions similar to those of established antagonists GLP-1(9-36)amide and exendin (9-39). *Metabolism*, 53: 252-259; 2004.
248. Marenah, L., Orr, D.F., McClean, S., Flatt, P.R., Shaw, C. and Abdel-Wahab, Y.H.A. Brevinin-1 and multiple insulin-releasing peptides in the skin of the frog *Rana palustris*. *J. Endocrinol.* 181: 347-354; 2004.
249. Green, B.D., Mooney, M.H., Gault, V.A., Bailey, C.J., Irwin, N., Harriott, P., Greer, B., Flatt, P.R. and O'Harte, F.P.M. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate derivitised native and Ala⁸-substituted GLP-1 analogues. *Biological Chemistry* 385: 169-177; 2004.
250. Dixon, G., Nolan, J., McClenaghan, N.H., Flatt, P.R. and Newsholme, P. Arachidonic acid, palmitic acid and glucose are important for the modulation of clonal pancreatic beta cell insulin secretion, growth and viability. *Clin. Science*, 106: 191-199; 2004.

251. Liu, H-K., Green, B.D., Gault, V.A., McCluskey, J.T., McClenaghan, N.H., O'Harte, F.P.M. and Flatt, P.R.
N-acetyl-GLP-1: a DPP IV resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell associated gene expression.
Cell Biol. Int. 28: 69-73; 2004.
252. Marenah L, Orr D.F, McClean S, Shaw, C., Flatt P.R and Abdel-Wahab Y.H.A
Skin secretions of *Bombina variegata* frog contain multiple insulin releasing peptides including bombesin and entirely novel insulintropic structures.
Biological Chemistry 385: 315-321; 2004.
253. Ball, A.J., McCluskey, J.T., Flatt, P.R. and McClenaghan, N.H.
Chronic exposure to tolbutamide and glibenclamide impairs insulin secretion but not expression of K-ATP channel components.
Pharmac. Res. 50: 41-46; 2004.
254. Liu, H-K., Green, B.D., McClenaghan, N.H., McCluskey, J.T. and Flatt, P.R.
Long-term beneficial effects of vanadate, tungstate and molybdate on insulin secretion and function of cultured beta cells.
Pancreas, 28: 364-368; 2004.
255. Ball, A.J., Flatt, P.R. and McClenaghan, N.H.
Acute and long-term effects of nateglinide on insulin secretory pathways.
Br. J Pharmacol. 142: 367-373; 2004.
256. Liu, H-K., Green, B.D., Flatt, P.R., McClenaghan, N.H. and McCluskey, J.T.
Effects of long-term exposure to nicotinamide and sodium butyrate on growth, viability and the function of clonal insulin-secreting cells.
Endocrine Res. 30: 61-68; 2004.
257. Green, B.D., Gault, V.A., Flatt, P.R., Harriott P., Greer, B. and O'Harte, F.P.M.
Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion and in vivo antidiabetic actions following substitution of Ala⁸/Ala² for 2-aminobutyric acid.
Arch. Biochem. Biophys. 428: 136-43; 2004.
258. Irwin N., Gault, V.A., Green, B.D., Greer, B., McCluskey, J.T., Harriott, P., O'Harte, F.P.M. and Flatt, P.R.
Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.
Biol. Chem. 385: 845-852; 2004.
259. Ball, A.J., Flatt, P.R. and McClenaghan, N.H.
Alterations of insulin secretion following long-term manipulation of ATP-sensitive potassium channels by diazoxide and nateglinide.
Biochem. Pharmacol, 69: 59-63; 2005.
260. Graham, C., Irvine, A.E., McClean, S., Richter, S., Lapin, T.R.J., Flatt, P.R. and Shaw, C.
Peptide tyrosine arginine, a potent immunomodulatory peptide isolated and structurally characterised from the skin secretions of the dusky gopher frog, *Rana servosa*.
Peptides, 26: 737-743; 2005.
261. Lindsay, J.R., Duffy, N., McKillop, A.M., Ardill, J., Flatt, P.R. and Bell, P.M.
Inhibition of dipeptidyl peptidase IV (DPPIV) activity by oral metformin in type 2 diabetes.
Diabetic Med., 22: 654-657; 2005.

262. Irwin, N., Green, B.D., Gault, V.A., Greer, B., Harriott, P., Bailey, C.J., Flatt, P.R. and O'Harte, F.P.M.
Degradation, insulin secretion and antihyperglycaemic actions of two palmitate-derivatised N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide (GIP).
J. Med. Chem. 48: 1244-1250; 2005.
263. Green, B.D., Lui, H.K., McCluskey, J.T., Duffy, N.A., O'Harte, F.P.M., McClenaghan, N.H. and Flatt, P.R.
Function of long-term GLP-1 treated pancreatic beta cells is improved by preventing DPP IV mediated degradation of GLP-1.
Diabetes, Obesity Metab. 7: 563-569; 2005.
264. Green, B.D., Irwin, N., Gault, V.A., Bailey, C.J., O'Harte, F.P.M. and Flatt, P.R.
Chronic treatment of ob/ob mice with exendin(9-39) suggests a minor role of endogenous GLP-1 in metabolic abnormalities of obesity-diabetes.
J. Endocrinol., 185: 307-317; 2005.
265. Marenah L, Shaw C, Orr D.F, M'CLean S, Flatt P.R and Abdel-Wahab Y.H.A
Characterisation of naturally occurring peptides in the skin secretion of *Rana pipiens* frog reveal pipinin-1 as novel insulin releasing agent:
J. Peptide Res. 66: 204-210; 2005.
266. Gault, V.A., Irwin, N., Green, B.D., McCluskey, J.T., Greer, B., Bailey, C.J., Harriott, P., O'Harte, F.P.M. and Flatt, P.R.
Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-diabetes.
Diabetes 54: 2436-2446; 2005.
267. Green, B.D., Gault, V.A., O'Harte, F.P.M. and Flatt, P.R.
A comparison of the cellular and biological properties of DPP IV-resistant N-glucitol analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Diabetes, Obesity Metab. 7: 595-604; 2005.
268. Abdel-Wahab, Y.H.A., Marenah, L., Orr, D.F., Shaw, C. and Flatt, P.R.
Isolation and structural characterisation of a novel 13 amino acid insulin-releasing peptide from the skin secretions of *Agalychnis calcarifer*.
Biol Chem. 386: 581-587; 2005.
269. Green, B.D., Irwin, N., Gault, V.A., O'Harte, F.P.M. and Flatt, P.R.
Development and therapeutic potential of incretin hormone analogues for type 2 diabetes.
Br. J. Diab. Vasc. Dis. 5: 134-140; 2005.
270. Irwin, N., Green, B.D., Mooney, M., Greer, B., Harriott, P., Bailey, C.J., Gault, V.A., O'Harte, F.P.M. and Flatt, P.R.
A novel long-acting agonist of glucose-dependent insulinotropic polypeptide (GIP) suitable for once daily administration in type 2 diabetes.
J. Pharmacol. Exp. Ther. 314: 1187-1194; 2005.
271. Cunningham, G., McClenaghan, N.H., Flatt, P.R. and Newsholme, P.
L-alanine induces changes in metabolic and signal transduction gene expression in a clonal pancreatic beta-cell line and protects from proinflammatory cytokine-induced apoptosis.
Clin. Science, 109: 447-455; 2005.

272. Marenah, L., Flatt, P.R., Orr, D.F., Shaw, C. and Abdel-Wahab, Y.H.A.
Isolation and structural characterisation of novel Rugosin-A like insulinotropic peptide from the skin secretions of *Rana saharica* frog.
Peptides 26: 2117-2123; 2005.
273. Irwin, N., Gault, V.A., Green, B.D., Greer, B., Harriott, P., Bailey, C.J., Flatt, P.R. and O'Harte, F.P.M..
Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL¹⁶) and N-AcGIP(LysPAL³⁷).
Biol. Chem. 386: 679-687; 2005.
274. Liu, H-K., Green, B.D., McClenaghan, N.H., McCluskey, J.T. and Flatt, P.R.
Deleterious effects of dehydroepiandrosterone sulphate and dexamethasone on rat insulin-secreting cells under in vitro culture condition.
Bioscience Rep. 26: 31-38; 2006.
275. McKillop, A.M., Lindsay, J.R., Au, S., Mahood, K.I., O'Harte, F.P.M., Flatt, P.R. and Bell, P.M.
Meal-dependent regulation of circulating glycated insulin in type 2 diabetic subjects.
Horm. Metabol. Res. 38: 94-97; 2006.
276. Irwin, N., Green, B.D., Gault, V.A., O'Harte, F.P.M., Harriott, P and Flatt, P.R.
Effects on glucose homeostasis and insulin secretion of short term up-regulation of the glucose dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(Lys PAL³⁷) in normal mice.
Peptides 27: 893-900; 2006.
277. Mathews, J.N., Flatt, P.R. and Abdel-Wahab, Y.H.A.,
Asparagus adscendens (Shewta musali) stimulates insulin secretion, insulin action and inhibits starch digestion.
Br J Nutr. 95: 576-581; 2006.
278. Marenah, L., Flatt, P.R., Orr, D.F., Shaw, C. and Abdel-Wahab, Y.H.A.
Skin secretions of *Rana saharica* frogs reveal antimicrobial peptides Esculentins-1 and 1B and Brevinins-1E and 2EC with novel insulin releasing activity:
J. Endocrinol. 188: 1-9; 2006.
279. Patterson, S., Flatt, P.R., Brennan, L., Newsholme, P. & McClenaghan, N.H.
Detrimental actions of metabolic syndrome risk factor, homocysteine, on insulin secretion and pancreatic beta cell glucose metabolism.
J. Endocrinol. 189: 301-310; 2006.
280. Irwin, N., O'Harte, F.P.M., Gault, V.A., Mooney, M.H., Green, B.D., Greer, B., Harriott, P., Bailey, C.J. and Flatt, P.R.
Development and characterization of novel long-acting fatty acid derivatised analogs of glucose-dependent insulinotropic polypeptide (GIP) with improved antidiabetic potential.
J. Med. Chem. 49: 1047-1054; 2006.
281. Graham, C., Richter, S.C., O'Kane, E., Flatt, P.R. and Shaw, C.
Histamine-releasing and antibacterial peptides from the skin secretions of the dusky gopher frog, *Rana sevosa*.
Peptides, 27: 1313-1319; 2006.

282. Green, B.D., Irwin, N., Gault, V.A., O'Harte, F.P.M. and Flatt, P.R.
Pituitary adenylate cyclase activating protein (PACAP): Assessment of dipeptidyl peptidase IV degradation, insulin releasing activity and antidiabetic potential.
Peptides, 27: 1349-1358; 2006.
283. Irwin, N., Green, B.D., Gault, V.A., Harriott, P., O'Harte, F.P.M. and Flatt, P.R.
Stable agonist of glucose-dependent insulinitropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not normal glucose tolerance in aging mice.
Exp. Gerontology 41: 151-156; 2006.
284. Alana, I., Parker, J.C., Gault, V.A., Flatt, P.R., O'Harte, F.P.M., Malthouse, J.P.G. and Hewage, C.
NMR and alanine scan studies of glucose-dependent insulinitropic polypeptide.
J. Biol. Chem. 281: 16370-16376; 2006.
285. Hannan, J.M.A., Marenah, L., Ali, L., Rokeya, B., Flatt, P.R. and Abdel-Wahab, Y.
Ocimum sanctum leaf extracts stimulate insulin secretion from perfused pancreas, isolated islets and clonal beta cells.
J. Endocrinol. 189:127-136; 2006.
286. Irwin, N., Green, B.D., Parker, J.C., Gault, V.A., O'Harte, F.P.M. and Flatt, P.R.
Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent polypeptide, GIP(1-16) and (Pro³)GIP(1-16).
Reg Peptides, 135: 45-53; 2006.
287. Patterson, S., Flatt, P.R. and McClenaghan, N.H.
Homocysteine and other structurally diverse amino thiols can alter pancreatic beta cell function without evoking cellular damage.
Biochem. Biophys. Acta, 189: 301-310; 2006.
288. Conlon, J.M., Patterson, S. and Flatt, P.R.
Major contributions of comparative endocrinology to the development and exploitation of the incretin concept.
J. Exp. Zoolog. A Comp. Exp. Biol. 305: 781-786; 2006.
289. Green, B.D., Lavery, K.S., Irwin, N., O'Harte, F.P.M., Harriott, P., Greer, B., Bailey, C.J. and Flatt, P.R.
Novel GLP-1 analogue, (Val⁸)GLP-1, results in significant improvements of glucose tolerance and pancreatic beta cell function after 3 weeks daily administration in obese diabetic (ob/ob) mice.
J. Pharmacol. Exp. Therap. 318: 914-921; 2006.
290. Marenah, L., McCluskey, J.T., Abdel-Wahab, Y.H.A., O'Harte, F.P.M., McClenaghan, N.H. and Flatt, P.R.
Stable analogue of glucose-dependent insulinitropic polypeptide, GIP(LysPAL¹⁶), enhances functional differentiation of mouse embryonic stem cells into cells expressing specific islet genes and hormones.
Biol. Chem. 387: 941-947; 2006.
291. Hannan, J.M.A., Ali, L., Khaleque, J., Akhter M., Flatt, P.R. and Abdel-Wahab, Y.
Aqueous extract of *Platago ovata* husk reduces hyperglycaemia in type 1 and type 2 diabetes by inhibition of intestinal glucose absorption.
Br. J. Nutr. 96: 131-137; 2006.
292. Green, B.D., Irwin, N., Cassidy, R.S. and Flatt, P.R.

- Long-term administration of PACAP receptor antagonist, PACAP(6-27) impairs glucose tolerance and insulin sensitivity in obese diabetic (ob/ob) mice.
Peptides 27: 2343-2349; 2006.
293. McClenaghan N.H., Flatt, P.R. and Ball, A.J.
GLP-1 augments K-ATP channel-dependent and -independent actions of glucose, sulphonylureas and nateglinide.
J. Endocrinol. 190: 889-896; 2006.
 294. Irwin, N., Clarke, G., Green, B.D., Greer, B., Harriott, P., Gault, V.A., O'Harte, F.P.M. and Flatt, P.R.
Evaluation of the antidiabetic activity of DPP-IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Biochem. Pharmac. 72: 719-728; 2006.
 295. Green, B.D., Duffy, N.A., Gault, V.A., O'Harte, F.P.M. and Flatt, P.R.
Inhibition of dipeptidyl peptidase –IV (DPP IV) activity by metformin enhances the antidiabetic effects of glucagons-like peptide-1 (GLP-1).
Eur. J. Pharmacol. 547: 192-199; 2006
 296. Corless, M., McClenaghan, N.H., Flatt, P.R. and Newsholme, P.
Glutamine regulates expression of key transcription factor, signal transduction, metabolic gene and protein expression in a clonal pancreatic beta cell line.
J. Endocrinol. 190: 719-727; 2006.
 297. Brennan, L., Hewage, C., Malthouse, J.P.G., McClenaghan, N.H., Flatt, P.R. and Newsholme, P.
Investigating the effects of glibenclamide and tolbutamide on beta cell metabolism using NMR spectroscopy.
FEBS J. 273: 5160-5168; 2006.
 298. Parker, J.C., Lavery, K.S., Irwin, N., Green, B.D., Greer, B., Harriott, P., O'Harte, F.P.M., Gault, V.A. and Flatt, P.R.
Effects of daily treatment with naturally-occurring N-terminally truncated metabolites of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36), on insulin secretion and glucose homeostasis in ob/ob mice.
J. Endocrinol., 191: 93-100; 2006.
 299. Hannan, J.M.A., Marenah, L., Ali, L., Rokeya, B., Flatt, P.R. and Abdel-Wahab, Y.
Insulin secretory actions of extracts of Asparagus racemosus root in perfused pancreas, isolated islets and clonal pancreatic beta cells.
J. Endocrinol. 192: 159-168; 2007
 300. Hannan, J.M.A., Ali, L., Rokeya, B., Khaleque, J., Akhter M., Flatt, P.R. and Abdel-Wahab, Y.
Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in type 1 and type 2 diabetes by delaying carbohydrate digestion, absorption and enhancing insulin action.
Br. J. Nutr. 97: 514-521; 2007.
 301. Patterson, S., Flatt, P.R. and McClenaghan, N.H.
Homocysteine-induced impairment of pancreatic beta-cell responsiveness to a range of physiological and pharmacological insulin secretagogues is not reversed by catalase.
Pancreas, 34: 144-151; 2007.

302. Parker, J.C., Irwin, N., Lavery, K.S., Green, B.D. O'Harte, F.P.M., Gault, V.A. and Flatt, P.R. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro)³GIP and exendin(-9-39)amide in obese diabetic *ob/ob* mice. *Biol. Chem.* 388: 221-226; 2007.
303. Gault, V.A., Hunter, K., Irwin, N., Greer, B., Harriott, P., O'Harte, F.P.M. and Flatt, P.R. Characterisation and glucoregulatory actions of a novel acylated form of the (Pro)³GIP receptor antagonist in type 2 diabetes. *Biol. Chem.* 388: 173-179; 2007
304. Irwin, N., McClean, P.L., Harriot, P. and Flatt, P.R. Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice. *Exp. Gerontology* 42: 296-300; 2007.
305. Gault, V.A., McClean, P.L., Irwin, N., Power, G.J., McCluskey, J.T. and Flatt, P.R. Effects of sub-chronic treatment with the long-acting GIP receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocin-induced diabetes. *Pancreas* 35: 73-79; 2007.
306. McClean, P.L., Gault, V.A., Irwin, N., McCluskey, J.T. and Flatt, P.R. Daily administration of the GIP-R antagonist, (Pro)³GIP in streptozotocin induced diabetes suggests insulin-dependent mechanisms are critical to the anti-obesity-diabetes actions of (Pro)³GIP. *Diabetes Obes. Metab.* 10: 336-342; 2008
307. Green, B.D., Irwin, N. and Flatt, P.R. Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice. *Peptides* 28: 981-987; 2007.
308. Irwin, N., McClean, P.L., Cassidy, R.C., O'Harte, F.P.M., Green, B.D., Gault, V.A., Harriott, P. and Flatt, P.R. Comparison of the antidiabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (*ob/ob*) mice: Studies with DPP IV resistant N-AcGIP and exendin(1-39)amide. *Diabetes Metab. Res Rev.* 23: 572-579; 2007.
309. Irwin, N., McClean, P.L. and Flatt, P.R. Comparison of the sub-chronic antidiabetic effects of DPP IV resistant GIP and GLP-1 analogues in obese diabetic (*ob/ob*) mice. *J. Pept. Sci.* 13: 400-405; 2007.
310. Gault, V.A., Hunter, K., Irwin, N., Green, B.D., Greer, B., Harriott, P., O'Harte, F.P.M. and, Flatt, P.R. Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists. *Arch. Biochem. Biophys.* 461: 263-274; 2007.
311. O'Harte, F.P.M., Hunter, K., Gault, V.A., Irwin, N., Green, B.D., Greer, B., Harriott, P., Bailey, C.J. and Flatt, P.R. Antagonistic effects of two novel GIP analogues, (Hyp³)GIP and (Hyp³)GIPLys¹⁶PAL on the biological actions of GIP and longer term effects in diabetic *ob/ob* mice. *Am. J. Physiol.* 292: E1674-E1682; 2007.
312. Gault, V.A., McClean, P.L., Cassidy, R.C., Irwin, N. and Flatt, P.R.

- Chemical GIP receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high fat and cafeteria diets.
Diabetologia 50: 1752-1762; 2007.
313. Irwin, N., McClean, P.L., O'Harte, F.P.M., Gault, V.A., Harriott, P. and Flatt, P.R.
Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist, (Pro³)GIP, prevents the development of diabetes and related metabolic abnormalities associated with genetically-inherited obesity in ob/ob mice.
Diabetologia 50: 1532-1540; 2007.
 314. Patterson, S., Flatt, P.R. and McClenaghan, N.H.
Major metabolic homocysteine-derivative, homocysteine thiolactone, exerts changes in pancreatic beta-cell glucose-sensing, cellular signal transduction and integrity.
Arch. Biochem. Biophys. 461: 287-293; 2007.
 315. Patterson, S., Scullion, S.M., McCluskey, J.T., Flatt, P.R. and McClenaghan, N.H.
Prolonged exposure to homocysteine results in diminished but reversible pancreatic beta-cell responsiveness to insulinotropic agents.
Diabetes Metab. Res. Rev. 23: 324-334; 2006.
 316. Flatt, P.R.
Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): Evidence and clinical opportunity for development of new obesity-diabetes drugs?
Diab. Vasc. Dis. Res. 4: 151-153; 2007.
 317. Kiely, A., McClenaghan, N.H., Flatt, P.R. and Newsholme, P.
Pro-inflammatory cytokines increase glucose, alanine and triacylglycerol utilization but inhibit insulin secretion in a clonal pancreatic beta-cell line.
J. Endocrinol., 195: 113-123; 2007.
 318. Abdel-Wahab, Y.H.A., Marenah, L., Flatt, P.R. and Conlon, J.M.
Insulin-releasing properties of the temporin family of antimicrobial peptides.
Protein Pept. Letts. 14: 702-707; 2007.
 319. Duffy, N.A., Green, B.D., Irwin, N., Gault, V.A., McKillop, A.M., O'Harte, F.P.M. and Flatt, P.R.
Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Eur J. Pharmacol. 568: 278-286; 2007.
 320. McClean, P.L., Irwin, N., Cassidy, R.S., Holst, J.J., Gault, V.A. and Flatt, P.R.
GIP receptor antagonism using (Pro³)GIP reverses obesity, insulin resistance and associated metabolic disturbances induced in mice by prolonged consumption of high fat diet.
Am. J. Physiol., 293: E1746-1755; 2007.
 321. Irwin, N., Hunter, K. and Flatt, P.R.
Comparison of the sub-chronic metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice.
Peptides 28: 2192-2198; 2007.
 322. Liu, H.K., McCluskey, J.T., McClenaghan, N.H. and Flatt, P.R.
Streptozotocin-resistant BRIN-BD11 cells possess wide spectrum of toxin tolerance and enhanced insulin-secretory capacity.
Endocrine 32: 20-29; 2007.

323. McClean, P.L., Gault, V.A., Irwin, N., McCluskey, J.T. and Flatt, P.R.
Daily administration of the GIP-R antagonist, (Pro)³GIP in streptozotocin induced diabetes suggests insulin-dependent mechanisms are critical to the anti-obesity-diabetes actions of (Pro)³GIP.
Diabetes Obes. Metab. 10: 336-342; 2008
324. McKillop, A.M., Duffy, N.A., Lindsay, J.R., O'Harte, F.P.M., Bell, P. and Flatt, P.R.
Decreased dipeptidyl peptidase IV activity and GLP-1 degradation in type 2 diabetic subjects.
Diabetes Clin.Res.Pract. 79: 79-85; 2008.
325. Cassidy, R.S., Irwin, N. and Flatt, P.R.
Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets.
Biol. Chem. 389: 189-193; 2008.
326. Liu, H.K., McCluskey, J.T., McClenaghan, N.H. and Flatt, P.R.
Iterative exposure of clonal BRIN-BD11 cells to ninhydrin enables selection of robust toxin-resistant pancreatic beta cells but with decreased gene expression and insulin-secretory function.
Pancreas 36: 294-301; 2008.
327. Abdel-Wahab, Y.H.A., Power, G.J., Flatt, P.R., Woodhams, D.C., Rollins-Smith, L.A. and Conlon, J.M.
A peptide of the phylloepitin family from the skin of the frog *Hylomantis lemur* (Phyllomedusinae) with potent in vitro and in vivo insulin-releasing activity.
Peptides 29: 2136-2143; 2008.
328. Irwin, N., Hunter, K., Frizzell, N. and Flatt, P.R.
Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice.
Eur. J. Pharmacol. 581: 226-233; 2008.
329. Irwin, N., Hunter, K. and Flatt, P.R.
Comparison of independent and combined metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice.
Peptides 29: 1036-1041; 2008.
330. Abdel-Wahab, Y.H.A., Power, G.J., Ng, M.T., Flatt, P.R. and Conlon, M.J.
Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-substituted analogue.
Biol. Chem. 389: 143-148; 2008.
331. McClean, P.L., Irwin, N., Hunter, K., Gault, V.A. and Flatt, P.R.
(Pro³)GIP[mPEG]: Novel long-acting mini-PEGylated gastric inhibitory polypeptide antagonist for obesity-diabetes therapy.
Br. J. Pharmacol. 155: 690-701; 2008.
332. Conlon, J.M. Power, G.M., Abdel-Wahab, Y.H.A., Flatt, P.R., Jiansheng, H., Coquet, L., Leprince, L., Jouenne, T. and Vaudry, H.
A potent, non-toxic insulin-releasing peptide isolated from an extract of the skin of the Asian frog, *Hylarana guntheri* (Anura:Ranidae).
Regul. Pept. 151 (1-3):153-159, 2008.
333. McClean, P.L., Irwin, N., Hunter, K., Gault, V.A. and Flatt, P.R.

- (Pro³)GIP[mPEG]: Novel long-acting mini-PEGylated gastric inhibitory polypeptide antagonist for obesity-diabetes (diabesity) therapy.
Br. J. Pharmac. 155: 690-701; 2008.
334. Taylor, A., Irwin, N., McKillop, A.M., Flatt, P.R. and Gault, V.A.
Sub-chronic administration of 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Biological Chemistry 389: 441-445; 2008.
 335. Gault, V.A., Kerr, B.D., Irwin, N. and Flatt, P.R.
C-terminal mini-PEGylation of glucose-dependent insulintropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.
Biochem. Pharmacol. 75: 2325-2333; 2008.
 336. Irwin, N., McClean, P.L., Patterson, S., Hunter, K. and Flatt, P.R.
Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes.
Biological Chemistry 390: 75-80; 2009.
 337. Conlon, J.M., Abdel-Wahab, Y.H.A., Flatt, P.R., Leprince, J., Vaudry, H., Jouenne, T. and Condamine, E.
A glycine-leucine-rich peptide structurally related to the plasticins from skin secretions of the frog *Leptodactylus laticeps* (Leptodactylidae).
Peptides 30: 888-892; 2009.
 338. McClenaghan, N.H., Scullion, S.M., Mion, N., Hewage, C., Malthouse, J.P.G., Flatt, P.R., Newsholme, P and Brennan, L.
Prolonged alanine exposure induces changes in metabolism, Ca²⁺ handling and desensitization of insulin secretion in clonal pancreatic beta cells
Clin. Sci. 116: 341-351; 2009.
 339. Irwin, N., Hunter, K., Frizzell, N. and Flatt, P.R.
Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice.
Regul. Pept. 153: 70-76; 2009.
 340. Kerr, B.D., Irwin, N., Flatt, P.R., Gault, V.A.
Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance.
Peptides 30: 219-225; 2009.
 341. Bender, K., Maechler, P., McClenaghan, N.H., Flatt, P.R. and Newsholme, P.
Overexpression of the malate-aspartate NADH shuttle member Aralar1 in the clonal beta cell line BRIN-BD11 enhances amino acid stimulated insulin secretion and cell metabolism.
Clin. Sci. 117: 321-330; 2009.
 342. Irwin, N., McClean, P.L., Hunter, K. and Flatt, P.R.
Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat fed mice.
Diabetes. Obes. Metab. 11: 603-610; 2009.
 343. Kerr, B.D., Irwin, N., O'Harte, F.P.M., Bailey, C.J., Flatt, P.R. and Gault, V.A.
Novel fatty acid derivatised analogues of glucose-dependent insulintropic polypeptide with improved antihyperglycaemic and insulintropic properties.
Biochem. Pharmacol. 78: 1008-1016; 2009.

344. Kiely, A., Robinson, A., McClenaghan, N.H., Flatt, P.R. and Newsholme, P.
Toll-like receptor agonist induced changes in clonal rat BRIN-BD11 beta cell insulin secretion and signal transduction.
J. Endocrinol. 202: 365-373; 2009.
345. Taylor, A.I., Frizzell, N., McKillop, A.M., Flatt, P.R. and Gault, V.A.
Effect of RU483 on hepatic and adipocyte gene expression and improves diabetes control in obesity-type 2 diabetes.
Horm. Metabol. Res. 41: 899-904; 2009.
346. McKillop, A.M., Duffy, N.A., Lindsay, J.R., Green, B.D., Patterson, S., O'Harte, F.P.M., Bell, P.M. and Flatt, P.R.
Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and GIP degradation.
Eur. J. Endocrinol. 161: 877-885; 2009
347. Kasabri, V., Flatt, P.R. and Abdel-Wahab, Y.H.A.
Terminalia bellerica stimulates the secretion and action of insulin and inhibits starch digestion and protein glycation in vitro.
Br. J. Nutr. 103: 212-217; 2010
348. Irwin, N., Flatt, P.R., Patterson, S. and Green, B.D
Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.
Eur. J. Pharmacol. 628: 268-273; 2010.
349. Kelly, C., Guo, H., McCluskey, J.T., Flatt, P.R. and McClenaghan, N.H.
Comparison of insulin release from MIN6 pseudoislets and pancreatic islets of Langerhans reveals importance of homotypic cell interactions.
Pancreas, 80: 396-401; 2010.
350. Abdel-Wahab, Y.H.A., Patterson, S., Flatt, P.R. and Conlon, J.M.
Brevinin-2-related peptide and its [D4K] analog stimulate insulin release *in vitro* and improve glucose tolerance in mice fed a high fat diet.
Horm. Metabol. Res. 42: 652-656; 2010.
351. Montgomery, I.A., Irwin, N. and Flatt, P.R.
Active immunisation against (Pro3)GIP improves metabolic status in high-fat fed mice.
Diabetes, Obesity and Metabolism, 12: 744-751; 2010.
352. Gault, V.A., Porter, W.D., Flatt, P.R. and Holscher, C.
Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet.
Int. J. Obesity, 34: 1341-1344; 2010.
353. Subasinghage, A.P., Green, B.D., Flatt, P.R., Irwin, N. and Hewage, C
Metabolic and structural properties of human obestatin(1-23) and two fragment peptides.
Peptides, 31: 1697-1705; 2010.
354. Kerr, B.D., Flatt, P.R. and Gault, V.A. Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.
Biochemical Pharmacology, 80: 396-401; 2010.
355. Porter, W.D., Kerr, B.D., Flatt, P.R., Holscher, C. and Gault, V.A.

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance.
Diabetes Obesity and Metabolism, 12: 891-899; 2010.

356. Morgan, D., Hirata E.A., Graciano, M.F.R., Curi, R., Carpinelli, A.R., Flatt, P.R. and Newsholme, P.
Characterization of NADPH oxidase subunit isoforms in clonal rat insulin-secreting cells: Implications for beta cell function.
FEBS Letts., submitted.
357. Taylor, A.I., Irwin, N., McKillop, A.M., Flatt, P.R. and Gault, V.A. Evaluation of the degradation and metabolic effects of the gut peptide Xenin on insulin secretion, glycaemic control and satiety.
Journal of Endocrinology, 207: 87-93; 2010.
358. Kerr, B.D., Flatt, P.R. and Gault, V.A.
(D-Ser²)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with improved antihyperglycaemic, insulinotropic and anorexigenic actions.
Biochem. Pharmacol., 80: 1727-1735; 2010.
359. Kelly, C., Guo, H., McCluskey, J.T., Flatt, P.R. and McClenaghan, N.H.
Evaluation of heterotypic pseudoislets to study the role of glucagon and somatostatin secreting cells in the regulation of insulin release and beta-cell function.
Diabetes Res. Metab. Rev. 26: 525-533; 2010.
360. McKinney, J.M., Irwin, N., Flatt, P.R., Bailey, C.J. and McClenaghan, N.H.
Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal beta-cells
Biol. Chem. 391: 1451-1459; 2010.
361. Kelly, C., Flatt, P.R. and McClenaghan, N.H.
Cell-to-cell communication and cellular environment alter the somatostatin status of delta cells
Biochem. Biophys. Res. Commun., 399: 162-166; 2010.
362. Porter D.W., Irwin, N., Flatt, P.R., Holscher, C. and Gault, V.A.
Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high fat fed mice.
Eur. J. Pharmacol., 650: 688-693; 2011.
363. Irwin, N., McKinney, J.M., Bailey, C.J., Flatt, P.R. and McClenaghan, N.H.
Effects of metformin on BRIN-BD11 beta-cell insulin secretory desensitisation induced by prolonged exposure to sulphonylureas.
Diabetes, Obesity and Metabolism 12: 1066-1071; 2010.
365. Irwin, N., McKinney, J.M., Bailey, C.J., McClenaghan, N.H. and Flatt, P.R.
Acute and long term effects of peroxisome proliferator-activated receptor gamma activation on the function and insulin secretory responsiveness of clonal beta cells.
Horm. Metabol. Res. 43: 244-249; 2011.
366. Paget, M.B., Murray, H.E., Bailey, C.J., Flatt, P.R. and Downing, R.
Rotational co-culture of clonal beta cells with endothelial cells: effect of PPAR-gamma agonism in vitro on insulin and VEGF secretion.
Diabetes, Obesity and Metabolism 13: 662-668; 2011.

367. Hsu, C.J., Kuo, Y.H., Cheng, H.L., Flatt, P.R. and Liu, H.K.
Schizandra arisanensis extract attenuates cytokine-mediated cytotoxicity in insulin-secreting cells.
World J. Gastroenterol. 18: 6809-6818; 2012.
368. McCluskey, J., Hamid, M.H., Guo-Parke, H., McClenaghan, N.H., Gomis, R. and Flatt, P.R.
Development and functional characterisation of insulin-releasing human pancreatic beta cell lines produced by electrofusion.
J. Biol. Chem. 286: 21982-21992; 2011.
369. Irwin, N., Francis, J.M.E. and Flatt, P.R.
Alterations of glucose-dependent insulinotropic polypeptide (GIP) during cold acclimation in the rat.
Reg. Pept. 167: 91-96; 2011.
370. Mechkarska, M., Ojo, O.O., Meetani, M.A., Coquet, L., Jouenne, T., Abdel-Wahab, Y.H.A., Flatt, P.R., King, J.D. and Conlon, J.M.
Peptidomic analysis of skin secretions from the bullfrog *Lithobates catesbeianus* (Ranidae) identifies multiple peptides with potent insulin-releasing activity.
Peptides, 32: 203-208; 2011.
371. Gault, V.A., Porter, D.W., Irwin, N. and Flatt, P.R.
Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high fat fed mice.
J. Endocrinol. 208: 265-271; 2011.
372. Kerr, B.D., Flatt, A.J.S., Flatt, P.R. and Gault, V.A.
Characterisation and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide.
Biochem. Biophys. Res. Commun. 404: 870-876; 2011.
373. Gault, V.A., Kerr, B.D., Harriott, P. and Flatt, P.R.
Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in type 2 diabetes and obesity.
Clin. Sci, 121: 107-117; 2011.
374. Patterson, S., Irwin, N., Moffett, R.C., Scullion, S.M., Flatt, P.R. and McClenaghan, N.H.
Evaluation of N-methyl-D-aspartate (NMDA) receptors in insulin-secreting cells.
Eur J Pharmacol., submitted
375. Franklin, Z.J., McDonnell, B., Montgomery, I.A., Flatt, P.R. and Irwin, N.
Dual modulation of GIP and glucagon action by the low molecular weight compound 4-hydrobenzoic acid 2-bromobenzylidene hydrazine.
Diabetes, Obesity and Metabolism 13: 742-749; 2011.
376. Da Silva Krause, M., Bittencourt, A., Homem de Bittencourt, P.I., McClenaghan, N.H., Flatt, P.R., Murphy, C. and Newsholme, P.
Physiological concentrations of interleukin-6 directly promote insulin secretion, signal transduction, nitric oxide release and redox status in a clonal pancreatic beta-cell line and mouse islets.
J. Endocrinol. 214: 3021-311; 2012.
377. Hannan, J.M.A., Ali, L., Khaleque, J., Akhter, M, Flatt, P.R. and Abdel-Wahab, Y.H.A.
Antihyperglycaemic activity of *Asparagus racemosus* roots is partly mediated by inhibition of carbohydrate digestion and absorption, and enhancement of cellular insulin action.

- Br. J. Nutr. 107: 1316-1323; 2012.
378. Zahid, O.K., Mechkarska, M., Ojo, O.O., Abdel-Wahab, Y.H.A., Flatt, P.R., Meetani, M.A. and Conlon, J.M.
Caerulein- and xenopsin-related peptides with insulin-releasing activities from skin secretions of the clawed frogs, *Xenopus borealis* and *Xenopus amieti* (Pipidae).
Gen. Comp. Endocrinol., 172: 314-320; 2011.
 379. Krause, M.S., McClenaghan, N.H., Flatt, P.R., de Bittencourt Jr, P.I., Murphy, C. and Newsholme, P.
L-arginine is essential for pancreatic beta-cell functional integrity, metabolism and defence from inflammatory challenge.
J Endocrinol. 211: 87-97; 2011.
 380. Ojo, O.O., Abdel-Wahab, Y.H.A., Flatt, P.R., Mechkarska, M. and Conlon, J.M.
Tigerinin-1R: a potent, non-toxic insulin-releasing peptide isolated from the skin of the Asian frog, *Hoplobatrachus rugulosus*.
Diabetes Obes. Metab. 13(12):1114-1122; 2011.
 381. Irwin, N., Montgomery, I.A. and Flatt, P.R.
Evaluation of long-term effects of immunisation with conjugated GIP peptides on insulin resistance, metabolic dysfunction, energy balance and cognition in high fat fed mice.
Br. J. Nutr. 108: 46-56; 2012.
 382. Irwin, N., Francis, J.M.E. and Flatt, P.R.
Insulin modulates glucose-dependent insulinotropic polypeptide (GIP) secretion from enteroendocrine K cells in rats.
Biol Chem. 392:909-918; 2011.
 383. Scullion, S.M., Flatt, P.R., McClenaghan, N.H., Lenzen, S., Elsner, M., Gurgul-Convey, E.
Enhanced homocysteine toxicity to insulin-secreting BRIN-BD11 cells in combination with alloxan.
J Endocrinol. 214: 233-238; 2012.
 384. Martin, C.M., Gault, V.A., McClean, S., Flatt, P.R. and Irwin, N.
Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25.
Biochem Pharmacol. 84: 312-319; 2012.
 385. Porter, D., Faivre, E., Flatt, P.R., Hölscher, C. and Gault, V.A.
Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice.
Peptides. 35:1-8; 2012.
 386. Irwin, N., Frizzelle, P., Montgomery, I.A., Moffett, R.C., O'Harte, F.P.M. and Flatt, P.R.
Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in animal models of obesity-diabetes.
Diabetologia, 55: 2747-2758; 2012.
 387. Guo-Parke, H., McCluskey, J.T., Kelly, C., Hmid, M., McClenaghan, N.H. and Flatt, P.R.
Configuration of electrofusion-derived human insulin-secreting cell line as pseudoislets enhances functionality and therapeutic utility.
J. Endocrinol. 214: 257-265; 2012.

388. Porter W.D., Flatt, P.R., Holscher, C. and Gault, V.A.
Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.
Int J Obes. 37: 678-684; 2013.
389. Irwin N, Montgomery IA, O'Harte FP, Frizelle P, Flatt PR.
Comparison of independent and combined metabolic effects of sub-chronic modulation of CCK and GIP receptor action in obesity-related diabetes
Int J Obes. 37: 1058-1063; 2013.
390. Irwin N, Frizelle P, O'Harte FP, Flatt PR.
Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme resistant CCK-8 analogue, (pGlu-Gln)-CCK-8, in normal mice.
J. Endocrinol. 216: 53-59; 2013.
391. Irwin N, Montgomery IA, Moffett RC, Flatt PR.
Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
Biochem. Pharmacol. 85: 81-91; 2013.
392. Lennox R, Porter DW, Flatt PR, Gault VA.
(Val⁸)GLP-1-Glu-PAL: a GLP-1 agonist which improves hippocampal neurogenesis, glucose homeostasis and beta-cell function in high-fat fed mice.
ChemMedChem. 8: 595-602; 2013.
393. Srinivasan D, Mechkarska M, Abdel-Wahab YHA, Flatt PR, Conlon JM
Caerulein precursor fragment (CPF) peptides from the skin secretions of *Xenopus laevis* and *Silurana epitropicalis* are potent insulin-releasing agents.
Biochimie 95: 429-435; 2013.
394. Mabilletau G, Mieczkowska A, Irwin N, Flatt PR and Chappard D.
Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor.
J Endocrinol. 219: 59-68; 2013.
395. Martin CM, Irwin N, Flatt PR, Gault VA.
A novel acylated form of (D-Ala²)GIP with improved antidiabetic potential, lacking effect on body fat stores.
Biochim Biophys Acta. 1830: 3407-3413; 2013.
396. Irwin N, Montgomery IA, Flatt PR.
Comparison of the metabolic effects of sustained CCK1 receptor activation alone and in combination with upregulated leptin signalling in high-fat-fed mice.
Diabetologia. 56: 1425-1435; 2013.
397. Irwin N, Hunter K, Montgomery IA, Flatt PR.
Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Diabetes Obes Metab. 15: 650-659; 2013.
398. Montgomery IA, Irwin N, Flatt PR.
Beneficial effects of (pGlu-Gln)-CCK-8 on energy intake and metabolism in high fat fed mice are associated with alterations of hypothalamic gene expression.
Horm Metab Res. 45: 471-473; 2013.

399. Gaudin-Audrain C, Irwin N, Mansur S, Flatt PR, Thorens B, Baslé M, Chappard D, Mabillet G.
Glucose-dependent insulintropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice.
Bone. 53(1):221-230; 2013.
400. Irwin, N., Frizelle, P., O'Harte, F.P.M. & Flatt, P.R.
(pGlu-Gln)-CCK-8[mPEG]: a novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes.
Biochim. Biophys. Acta 1830: 4009-4016; 2013
401. Bhat VK, Kerr BD, Flatt PR & Gault VA.
A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Biochem. Pharmacol. 85: 1655-1662; 2013.
402. Bhat VK, Kerr BD, Vasu S, Flatt PR & Gault VA.
A DPPIV-resistant triple acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulintropic actions in high fat fed mice.
Diabetologia 56: 1417-1424; 2013.
403. Vasu S, McClenaghan NH, McCluskey JT & Flatt PR
Effects of lipotoxicity on novel insulin secreting human pancreatic beta cell line, 1.1B4.
Biol. Chem. 394: 909-918; 2013.
404. Ojo OO, Conlon JM, Flatt PR & Abdel-Wahab YHA.
Frog skin peptides (tigerinin-1R, magainin-AM1, AM2, CPF-AM1 and PGla-AM1) stimulate secretion of glucagon-like peptide 1 (GLP-1) by GLUTa cells.
Biochem Biophys Res Commun 431: 14-18; 2013.
405. Ojo OO, Abdel-Wahab YHA, Flatt PR and Conlon JM.
Insulintropic actions of the frog skin host-defense peptide alyteserin-2a: a structure-activity study.
Chem Biol Drug Design 82: 196-204; 2013.
406. Vasu S, Moffett RC, McCluskey JT, Hamid MH, Irwin N, Flatt PR.
Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice.
Gene Ther. 20: 1077-1084; 2013.
407. Mieczkowska A, Irwin N, Flatt PR, Chappard D and Mabillet G
Glucose-dependent insulintropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality.
Bone 56: 337-342; 2013.
408. McKillop AM, Moran BM, Abdel-Wahab YHA and Flatt PR.
Evaluation of the insulin-releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta cells, isolated islets and mice.
Br. J Pharmacol, 170: 978-990; 2013.
409. Moffett RC, Irwin N, Francis JME and Flatt PR
Functional alterations of glucose-dependent insulintropic polypeptide and expression of genes involved in mammary gland lipid metabolism during pregnancy and lactation.
PLoS One 8: e78560; 2013.

410. Vasu S, McClenaghan NH, McCluskey JM and Flatt PR.
Cellular responses of novel human pancreatic beta cell line 1,1B4 to hyperglycaemia.
Islets, 5: 170-177; 2013.
411. Gault VA, Bhat VK, Irwin N and Flatt PR
A novel GLP-1/glucagon hybrid peptide with triple-acting agonis activity at GIP, GLP-1 and
glucagon receptors and therapeutic potential in high fat fed mice.
J Biol Chem. 288: 35581-35591; 2013.
412. Gault VA, Bhat VK, Irwin N and Flatt PR
A novel GLP-1/glucagon hybrid peptide with triple-acting agonis activity at GIP, GLP-1 and
glucagon receptors and therapeutic potential in high fat fed mice.
J Biol Chem. 288: 35581-35591; 2013.
413. Moran BM, Abdel-Wahab YHA, Flatt PR and McKillop AM.
Activation of GPR119 by fatty acid agonists augments insulin release from clonal beta cells
and isolated pancreatic islets and improves glucose tolerance in mice.
Biol. Chem 395: 453-463; 2014.
414. Vasu S, McClenaghan NH, McCluskey JT & Flatt PR
Mechanisms of toxicity by pro-inflammatory cytokines in a novel human pancreatic beta cell
line, 1.1B4
Biochim Biophys Acta 1840: 136-145; 2014.
415. Moffett RC, Vasu S, Thoren, B., Drucker, D.J. and Flatt PR
Incretin receptor null mice reveal key role of GLP-1 but not GIP in pancreatic beta cell
adaptation to pregnancy.
PLos One, 9(6): e96863; 2014.
416. Pathak V, Vasu S, Flatt PR and Irwin N
Effects of chronic exposure to elevated glucose and free fatty acids on incretin receptor gene
expression and secretory responses to GIP and GLP-1 in clonal beta cells.
Diabetes Obes Metab. 16: 357-365; 2014.
417. Thomson, H.A.J., Ojo, O.O., Flatt, P.R. and Abdel-Wahab, Y.H.A.
Aqueous bark extracts of Terminalia arjuna stimulates insulin release, enhances insulin action
and inhibits starch digestion and protein glycation in vitro.
Austin J. Endocrinol. Diabetes 1: 1-6; 2014.
418. Mabilieu G, Mieczkowska A, Irwin N, Audran M, Flatt PR and Chappard D
Beneficial effects of an N-terminally modified GIP agonist on tissue level bone material
properties.
Bone 63: 61-68; 2014.
419. Kasabri, V., Flatt, P.R. and Abdel-Wahab, Y.H.A.
Emblica officinalis stimulates the secretion and action of insulin and inhibits starch digestion
and protein glycation in vitro.
Eur J Medicinal Plants 4: 753-770; 2014.
420. Kasabri, V., Flatt, P.R. and Abdel-Wahab, Y.H.A.
In vitro modulation of pancreatic insulin secretion and extrapancreatic insulin action,
enzymatic starch digestion and protein glycation by Terminalia chebula extracts.
Eur J Medicinal Plants 4: 771-782; 2014.
421. Martin C, Parthsarathy V, Pathak V, Gault VA, Flatt PR, Irwin N.

- Characterisation of the biological activity of xenin-25 degradation fragment peptides.
J Endocrinol. 221:193-200; 2014.
422. McKillop, A.M., Ng, M.T., Abdel-Wahab, Y.H.A. and Flatt, P.R.
Evidence for inhibitory autocrine effects of proinsulin C-peptide on pancreatic β -cell function and insulin secretion.
Diabetes Obes Metab. 16: 937-946; 2014.
 423. Srinivasan, D., Ojo, O.O., Abdel-Wahab, Y.H.A., Flatt, P.R., Guilhaudis, L. and Conlon, J.M.
Insulin-releasing and cytotoxic properties of the frog skin peptide, tigerinin-1R: A structure-activity study.
Peptides. 55: 23-31; 2014.
 424. Moran, B.M., Abdel-Wahab, Y.H.A., Flatt, P.R. and McKillop, A.M.
Evaluation of the insulin releasing and glucose lowering effects of GPR120 activation in pancreatic beta cells.
Diabetes Obes Metab. 16: 1128-1139; 2014.
 425. Kasabri, V., Flatt, P.R. and Abdel-Wahab, Y.H.A.
In vitro modulation of pancreatic insulin secretion, extrapancreatic insulin action and peptide glycation by Curcuma longa extracts.
J Exp Integ Med 4(3): 187-193; 2014.
 426. Vasu, S., Moffett, R.C., Thorens, B. and Flatt, P.R.
Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress.
PLoS One 9(6): e101005; 2014.
 427. Lennox, R., Porter, D.W., Flatt, P.R., Holscher C., Irwin, N. and Gault, V.A.
Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice.
Neuropharmacology 86: 22-30; 2014.
 428. Lynch, A.M., Pathak, N., Pathak, V., O'Harte, F.P.M., Flatt, P.R., Irwin, N. and Gault, V.A.
A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.
Diabetologia 57: 1927-1936; 2014.
 429. Lennox, R., Flatt, P.R. and Gault, V.A.
Lixisenatide improves recognition memory and exerts neuroprotective effects in high-fat fed mice.
Peptides 61: 38-47; 2014.
 430. Ojo, O.O., Srinivasan, D.K., Owlabi, B.O., Flatt, P.R. and Abdel-Wahab, Y.H.A.
Magainin-related peptides stimulate insulin release and improve glucose tolerance in high fat fed mice.
Protein Pept. Lett. 22: 256-263; 2014.
 431. Thomson, H.A.J., Ojo, O.O., Flatt, P.R. and Abdel-Wahab, Y.H.A.
Antidiabetic actions of aqueous bark extract of Swertia chirayita on insulin secretion, cellular glucose uptake and protein glycation.
J Exp Integ Med. 4: 268-272; 2014.

432. Lynch, A.M., Pathak, N., Flatt, Y.E., Gault, V.A., O'Harte, F.P.M., Irwin, N. and Flatt, P.R. Comparison of stability, cellular, glucose-lowering and appetite suppressing effects of oxyntomodulin analogues modified at the N-terminus. *Eur. J. Pharmacol.* 743: 69–78; 2014.
433. Moffett RC, Patterson S, Irwin N and Flatt PR. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes. *Diabetes Metab Res Rev.* 31: 248-255; 2015.
434. Hannan, J.M.A., Ojo, O.O., Ali, L., Rokeya, B., Khaleque, J., Akhter, M., Flatt, P.R. and Abdel-Wahab, Y. Mechanisms underlying antidiabetic effects of *Ocimum sanctum* leaf extracts in animal models of type 1 and type 2 diabetes. *Eur J Medicinal Plants* 5: 1-12; 2015.
435. Ojo, O.O., Srinivasan, D., Owolabi, B.O., Conlon, J.M., Flatt, P.R. and Abdel-Wahab, Y.H.A. Magainin-AM2 improves glucose homeostasis and islet beta cell function in high-fat fed mice. *Biochem Biophys Acta* 1850: 80-87; 2015.
436. Green, A.D., Vasu, S., McClenaghan, N.H. and Flatt, P.R. Pseudoislet formation enhances gene expression, insulin secretion and cytoprotective mechanisms of clonal human insulin secreting 1.1B4 cells. *Pflugers Arch.* 467: 2219-2228; 2015.
437. Pathak, V., Gault, V.A., Irwin, N. and Flatt, P.R. Antagonism of gastric inhibitory polypeptide by palmitoylated analogues of GIP with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice. *Mol Cell Endocrinol.* 401: 120-129; 2015.
438. Ojo, O.O., Srinivasan, D.K., Owolabi, B.O., Flatt, P.R. and Abdel-Wahab, Y.H.A. Beneficial effects of tigerinin-1R on glucose homeostasis and beta cell function in mice with diet-induced obesity-diabetes. *Biochemie* 109: 18-26; 2015.
439. Lennox, R., Moffett, R.C., Porter, D.W., Irwin, N., Gault, V.A. and Flatt, P.R. Effects of GIP receptor knockout and high-fat diet on cognitive function and hippocampal gene expression in mice. *Molec. Med. Rep.* 12: 1544-1548; 2015.
440. Mieczkowska, A., Mansur, S., Flatt, P.R., Thorens, B., Irwin, N., Chappard, D. and Mabileau, G. Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength. *Osteoporosis International*, 26: 209-218; 2015.
441. Gault, V.A., Martin, C., Flatt, P.R., Parthsarathy, V. and Irwin, N. Xenin-25[Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential. *Acta Diabetol*, 52: 461-471; 2015.
442. Moffett, R.C., Vasu, S. and Flatt, P.R.

Functional GIP receptors play a major role in islet compensatory response to high fat feeding in mice.

Biochem Biophys Acta 1850 (6): 12106-1214; 2015.

443. Gault, V.A., Lennox, R. and Flatt, P.R.
Sitagliptin, a DPP-IV inhibitor improves recognition memory, oxidative stress, hippocampal neurogenesis and up-regulates key genes involved in cognitive decline.
Diabetes Obes Metab., 17: 403-413; 2015.
444. Patterson, S., Irwin, N., Moffett, R.C., de Kort, M., Dokter, W.H.A., Bos, E.S., Miltenburg, A.M.M. and Flatt, P.R.
Pharmacological characterisation and antidiabetic activity of a long-acting GLP-1 analogue conjugated to an ATIII-binding polysaccharide.
Diabetes Obes. Metab, 17: 760-770; 2015.
445. Irwin, N., Patterson, S., de Kort, M., Moffett, R.C., Wisse, J.A.J., Dokter, W.H.A., Bos, E.S., Miltenburg, A.M.M. and Flatt, P.R.
Synthesis and evaluation of a series of long-acting glucagon-like peptide-1 (GLP-1) pentasaccharide conjugates for the treatment of type 2 diabetes.
Chem. Med. Chem., 10: 1424-1434; 2015.
446. Mieczkowska A, Mansur SA, Irwin N, Flatt PR, Chappard D and Mabilieu G
Alteration of the bone tissue material properties in type 1 diabetes mellitus: a Fourier-transform infrared microspectroscopy study.
Bone 76: 31-39; 2015.
447. Mansur SA, Mieczkowska A, Flatt PR, Chappard D, Irwin N and Mabilieu G
Stable incretin mimetics counter rapid deterioration of bone quality in type 1 diabetes mellitus.
J. Cell Physiol. 230: 3009-3018; 2015.
448. Moore, S.W.M., Bhat, V.K., Flatt, P.R., Gault, V.A. and McClean, S.
Isolation and characterization of insulin-releasing compounds from *Croalus adamanteus*, *Crotalus vegrandis* and *Bitis nasicornis* venom.
Toxicon, 101: 48-54; 2015.
449. Vasu, S., Moffett, R.C., McClenaghan, N.H. and Flatt, P.R.
Responses of GLP-1 secreting L-cells to cytotoxicity resemble pancreatic beta but not alpha cells.
J. Mol. Endocrinol. 54: 91-104; 2015.
450. Irwin, N., Pathak, V. Pathak, N., Gault, V.A and Flatt, P.R.
Sustained treatment with a stable, long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes.
Diabetes Obes. Metab. 17: 887-895; 2015.
451. Pathak, N. Pathak, V., Lynch, A.M., Irwin, N., Gault, V.A and Flatt, P.R.
Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat mice.
Mol. Cell Endocrinol. 412: 95-103; 2015.
452. Vasu, S., Moffett, R.C., McClenaghan, N.H. and Flatt, P.R.
Differential molecular and cellular responses of GLP-1 secreting L-cells and pancreatic alpha cells to glucotoxicity and lipotoxicity.
Exp. Cell Res. 336: 100-108; 2015.

453. Pathak, V., Gault, V.A., Flatt, P.R. and Irwin, N.
Sequential induction of beta cell rest and stimulation using stable GIP antagonist and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice.
Diabetologia. 58: 2144-2153; 2015.
454. Irwin, N., Pathak, V. and Flatt, P.R.
A novel CCK-8/GLP-1 hybrid peptide exhibiting prominent insulintropic, glucose lowering and satiety actions with significant therapeutic potential for obesity-diabetes.
Diabetes 64: 2996-3009; 2015.
455. Srinivasan, D., Ojo, O.O., Owolabi, B.O., Conlon, J.M., Flatt, P.R. and Abdel-Wahab, Y.H.A.
The frog skin host-defense peptide CPF-SE1 improves glucose tolerance, insulin sensitivity, islet function and decreases plasma lipids in high fat fed mice.
Eur. J. Pharmacol. 764: 38-47; 2015.
456. Ojo, O.O., Srinivasan, D., Owolabi, B.O., Vasu, S., Conlon, J.M., Flatt, P.R. and Abdel-Wahab, Y.H.A.
Esculentin-2Cha-related peptides modulate islet cell function and improve glucose tolerance in mice with diet-induced obesity and insulin resistance.
PLoS One. 10(10): e0141549; 2015.
457. Manzo G, Scorciapino MA, Srinivasan D, Attoub S, Mangoni ML, Rinaldi AC, Casu M, Flatt PR and Conlon JM
Conformational analysis of the host-defense peptides pseudhymenochirin-1Pb and-2Pa and design of analogs with insulin-releasing activities and reduced toxicities.
J Natural Products, 78: 3041-3048, 2015.
458. Pathak, V., Irwin, N., Gault, V.A. and Flatt, P.R.
(D-Ser²)Oxm[Lys³⁸-gamma-glu-PAL] improves hippocampal gene expression and cognition in a mouse model of type 1 diabetes.
J Exp Integ Med., 16: 1-5; 2016.
459. Moran, B.M., Abdel-Wahab, Y.H.A., Flatt, P.R. and McKillop, A.M.
GPR39 receptors and actions of trace metals on pancreatic beta cell function and glucose homeostasis.
Acta Diabetologica 53: 279-293; 2016.
460. Srinivasan, D., Ojo, O.O., Owolabi, B.O., Conlon, J.M., Flatt, P.R. and Abdel-Wahab, Y.H.A.
[I10W]tigerinin-1R improves glycaemic control, insulin sensitivity and pancreatic beta cell function in mice with diet-induced obesity.
Acta Diabetologica 53: 303-315; 2016.
461. Owolabi, B.O., Ojo, O.O., Srinivasan, D., Conlon, J.M., Flatt, P.R. and Abdel-Wahab, Y.H.A.
In vitro and in vivo insulintropic properties of the multifunctional frog skin peptide hymenochirin-1B: a structure-activity study.
Amino Acids 48: 535-547; 2016.
462. Mansur SA, Mieczkowska A, Flatt PR, Bouvard, B., Chappard D, Irwin N and Mabilieu G
A new stable GIP-oxintomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus.
Bone, 87: 102-113; 2016.
463. Millar, P.J.B., Pathak, V., Moffett, R.C., Pathak, N.M., Bjourson, A.J., O’Kane, MJ, Flatt, P.R. and Gault, V.A.

- Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice.
Mol Cell Endocrinol, 420: 37-45; 2016.
464. Martin C.M., Parthasarathy, V., Hasib A., Ng, M.T., McClean, S., Flatt, P.R. Gault VA., and Irwin, N.
Biological activity and antidiabetic potential of C-terminal octapeptide fragments of the gut-derived hormone xenin.
PLoS One, 11(3): e0152818; 2016.
 465. Parthasarathy V, Irwin N, Hasib A, Martin CM, McClean S, Bhat Ng NT, Flatt PR and Gault VA.
A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties.
Biochem Biophys Acta, 1860: 757-764; 2016.
 466. Green AD, Vasu S and Flatt PR
Functionality and antidiabetic utility of beta and L-cell containing pseudoislets.
Exp Cell Res, 344: 201-209; 2016.
 467. Owolabi, B.O., Ojo, O.O., Srinivasan, D., Conlon, J.M., Flatt, P.R. and Abdel-Wahab, Y.H.A.
Glucoregulatory, endocrine and morphological effects of [P5K]hymenochirin-1B in mice with diet-induced obesity and insulin resistance.
Naunyn-Schmiedeberg's Archives of Pharmac. 389: 769-781; 2016.
 468. Patterson S, Irwin N, Guo-Parke N, Moffett RC, Scullion SM, Flatt PR and McClenaghan NH
Evaluation of the role of N-methyl-D-aspartate (NMDA) receptors in insulin secreting beta - cells
Eur J Pharmacol, 771: 107-113; 2016.
 469. Green AD, Vasu S, Moffett RC and Flatt PR
Co-culture of clonal beta cells with GLP-1 and glucagon-secreting cell line impacts on beta cell insulin secretion, proliferation and susceptibility to cytotoxins.
Biochemie, 125: 119-125; 2016.
 470. Ojo, O.O., Srinivasan, D., Owolabi, B.O., McGahon M, Moffett RC, Curtis TM, Conlon, J.M., Flatt, P.R. and Abdel-Wahab, Y.H.A.
Molecular actions mediating the beneficial metabolic effects of [Arg⁴]tigerinin-1R in mice with diet-induced obesity and insulin resistance.
Biol. Chem. 397: 753-764; 2016.
 471. Moore, S.W.M., Bhat, V.K., Flatt, P.R., Gault, V.A. and McClean, S.
Isolation and characterization of insulin-releasing compounds from *Pseudechis australis* and *Pseudechis butleri* venom.
Int J Pep Res Therap, 22: 211-218; 2016.
 472. Vasu, S., McClenaghan, N.H. and Flatt, P.R.
Molecular mechanisms of toxicity and cell damage by chemicals in a human pancreatic beta cell line, 1.1B4.
Pancreas, 45: 1320-1329; 2016.
 473. O'Harte FPM, Ng MT, Lynch AM, Conlon JM and Flatt PR.
Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin-releasing and acute antihyperglycaemic activity in mice.
Mol Cell Endocrinol, 431:133-144; 2016.

474. Mabileau G, Perrot R, Flatt PR, Irwin N and Chappard D
High fat fed diabetic mice present with profound alterations of the osteocyte network
Bone, 90: 99-106; 2016.
475. Scullion, S.M., Hahn, C., Tyka, K., Flatt, P.R., McClenaghan, N.H., Lenzen, S. and Gurgul-Convey, E.
Improved antioxidant defense protects insulin-producing cells against homocysteine toxicity.
Chemico-Biological Interactions, 256: 37-46; 2016.
476. Kahn D, Vasu S, Moffett RC, Irwin N and Flatt PR.
Islet distribution of Peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta-cell function and survival.
Mol Cell Endocrinol, 436: 102-113; 2016.
477. O'Harte FPM, Ng MT, Lynch AM, Conlon JM and Flatt PR
Novel dogfish glucagon peptide analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
Diabetes Obes Metab, 18: 1013-1024; 2016.
478. Green AD, Vasu S, McClenaghan NH and Flatt PR
Implanting 1.1B4 human beta-cell pseudoislets improves glycaemic control in diabetic immune deficient mice.
World J Diabetes, 7(19): 523-533; 2016.
479. Mabileau G, Perrot R, Mieczkowska A, Boni S, Flatt PR, Irwin N and Chappard D
Glucose-dependent insulintropic polypeptide (GIP) dose-dependently reduces osteoclast differentiation and resorption.
Bone, 91: 102-112; 2016.
480. McKillop, A.M., Moran, B.M., Abdel-Wahab, Y.H.A., Gormley, N. and Flatt, P.R.
Metabolic effects of orally administered small molecule agonists of GPR55 and GRP119, Abn-CBD and AS-1269675, in multiple low dose streptozotocin-induced diabetic and incretin receptor knock-out mice.
Diabetologia, 59: 2674-2685; 2016.
481. Vasu S, McGahon M.K, Moffett RC, Curtis TM, Conlon JM, Abdel-Wahab YHA and Flatt PR.
Esculentin-2CHa(1-30) and its analogues: stability and mechanisms of insulintropic action.
J Endocrinol., 232: 423-435; 2017.
482. Hasib, A., Ng, N.T., Gault, V.A., Parthsarathy, V., Flatt, P.R. and Irwin, N.
An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high fat fed mice.
Diabetologia 60: 541-552; 2017.
483. Kahn D, Vasu S, Moffett RC, Irwin N and Flatt PR.
Influence of neuropeptide Y and pancreatic polypeptide on islet function and beta-cell survival.
Biochem Biophys Acta 1861: 749-758; 2017.
484. Vasu S, Ojo, OO, Moffett RC, Conlon JM, Flatt PR and Abdel-Wahab YHA
Antidiabetic actions of esculentin-2CHa(1-30) and its stable analogues in diet-induced model of obesity-diabetes.

Amino acids, 49: 1705-1717; 2017.

485. Millar PJB, Pathak NM, Parthasarathy V, Bjourson AJ, O’Kane MJ, Pathak V, Moffett RC, Flatt PR and Gault VA
Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice.
J Endocrinol, 234: 255-267; 2017.
486. Kahn D, Vasu S, Moffett RC, Gault VA, Irwin N and Flatt PR.
Role of locally produced xenin and the neurotensinergic system in pancreatic islet function and beta-cell survival.
Biol Chem, 399: 79-92; 2017.
487. Kahn D, Vasu S, Moffett RC, Irwin N and Flatt PR.
Differential expression of glucagon-like peptide-2 (GLP-2) is involved in pancreatic islet cell adaptations to stress and beta-cell survival.
Peptides, 95: 68-75; 2017.
488. Owolabi BO, Musale V, Ojo OO, Moffett RC, McGahon MK, Curtis TM, Conlon JM, Flatt PR and Abdel-Wahab YHA.
Actions of PGLa-AM1 and its [A14K] and [A20K] analogues and their therapeutic potential as antidiabetic agents.
Biochemie, 138: 1-12; 2017.
489. Parthasarathy V, Hogg C, Flatt PR and OHarte FPM
Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
Diabetes Obes Metab 20: 319-327; 2017.
490. Conlon JM, Musale V, Attoub S, Mangoni ML, Leprince J, Coquet L, Jouenne T, Abdel-Wahab YHA, Flatt PR and Rinaldi A.
Cytotoxic peptides with insulin-releasing activities from skin secretion of the Italian stream frog *Rana italic* (Ranidae).
J Peptide Sci. 23: 769-776; 2017.
491. OHarte FPM, Parthasarathy V, Hogg C and Flatt PR
Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin-releasing, glucose-lowering and anoexic properties.
Biochem Pharmacol, 146: 165-173; 2017.
492. Musale V, Casciaro B, Mangoni ML, Abdel-Wahab YHA, Flatt PR and Conlon JM
Assessment of the potential of temporin peptides from the frog *Rana temporaria* (Ranidae) as anti-diabetic agents.
J Peptide Sci, E-pub ahead of print, 2018.
493. Graham GV, Conlon JM, Abdel-Wahab YHA, Gault VA and Flatt PR
Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of GLP-1 receptor.
Peptides, 100: 182-189; 2018.
494. Pathak NM, Millar PJB, Pathak V, Flatt PR and Gault VA
Beneficial metabolic effects of dietary epigallocatechin gallate alone and in combination with exendin-4 in high fat diabetic mice.
Mol Cell Endocrinol, 460: 200-208; 2018.
495. Hasib A, Ng MT, Kahn D, Gault VA, Flatt PR and Irwin N

- A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, suppresses circulating lipids and restores GIP sensitivity in high fat fed mice.
Peptides, 100: 202-211; 2018.
496. McKillop AM, Stevenson CL, Moran B, Abdel-Wahab YHA and Flatt PR
Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion.
Peptides, 100: 165-172; 2018.
 497. Mohan S, Kahn D, Moffett RC, Irwin N and Flatt PR
Oxytocin is present in islets and plays a role in beta-cell function and survival.
Peptides, 100: 260-268; 2018.
 498. OHarte FPM, Parthsarathy V, Hogg C and Flatt PR
Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions.
Peptides, 100: 219-228; 2018.
 499. Kahn D, Vasu S, Moffett RC, Irwin N and Flatt PR
Expression of gastrin family peptides in pancreatic islets and their role in beta cell function and survival.
Pancreas, 47: 190-199; 2018.
 500. Musale V, Abdel-Wahab YHA, Flatt PR, Conlon JM and Mangoni ML
Insulinotropic, glucose-lowering and beta-cell anti-apoptotic actions of peptides related to esculentin-1a(1-21)NH₂
Amino Acids 50: 723-734; 2018.
 501. Pathak NM, Pathak V, Gault VA, McClean S, Irwin N and Flatt PR
Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
Biochem Pharmacol. 155: 264-274; 2018.
 502. Hasib A, Ng MT, Khan D, Gault VA, Flatt PR and Irwin N
Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln
Eur J Pharmacol 834: 126-135; 2018.
 503. O'Harte FPM, Parthsarathy V, Hogg C and Flatt PR
Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high fat fed mice.
PLoS One 13: e0202350; 2018.
 504. Lafferty RA, Flatt PR and Irwin N
C-terminal degradation of PYY peptides in plasma abolishes effects on satiety and beta cell function.
Biochem Pharmacol 158: 95-102; 2018.
 505. Graham GV, Conlon JM, Abdel-Wahab YH, Flatt PR.
Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy.
Peptides. 110:19-29; 2018.
 506. Pathak NM, Pathak V, Gault VA, McClean S, Irwin N, Flatt PR.
Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
Biochem Pharmacol. 155:264-274; 2018

507. Mansur SA, Mieczkowska A, Flatt PR, Chappard D, Irwin N and Mabilieu G
The GLP-1 receptor agonist exendin-4 ameliorates bone composition and tissue material properties in high fat fed diabetic mice.
Front Endocrinol (Lausanne) doi 10.3389/fendo.2019.0051; 2019.
508. Mansur SA, Mieczkowska A, Flatt PR, Chappard D, Irwin N and Mabilieu G
Sitagliptin alters bone composition in high fat fed mice.
Calcif Tissue Int 104: 437-448; 2019.
509. Lafferty RA, Gault VA, Flatt PR, Irwin N.
Effects of 2 novel PYY(1-36) analogues, (P₃L₃₁P₃₄)PYY(1-36) and PYY(1-36)(Lys₁₂PAL), on pancreatic beta-cell function, growth, and survival.
Clin Med Insights Endocrinol Diabetes. 12: 1-8; 2019
510. Moran BM, Miskelly MG, Abdel-Wahab YHA, Flatt PR, McKillop AM.
Zinc-induced activation of GPR39 regulates glucose homeostasis through glucose-dependent insulinotropic polypeptide secretion from enteroendocrine K-cells.
Biol Chem 400: 1023-1034; 2019
511. Hasib A, Ng MT, Tanday N, Craig SL, Gault VA, Flatt PR, Irwin N.
Exendin-4(Lys₂₇ PAL)/gastrin/xenin-8-Gln: A novel acylated GLP-1/gastrin/xenin hybrid peptide that improves metabolic status in obese-diabetic (ob/ob) mice.
Diabetes Metab Res Rev. 35(3):e3106; 2019
512. Graham GV, Conlon JM, Abdel-Wahab YH, Flatt PR.
Glucagon-like peptides-1 from phylogenetically ancient fish show potent anti-diabetic activities by acting as dual GLP1R and GCGR agonists.
Mol Cell Endocrinol. 480:54-64; 2019.
513. Musale V, Guilhaudis L, Abdel-Wahab YHA, Flatt PR, Conlon JM.
Insulinotropic activity of the host-defense peptide frenatin 2D: Conformational, structure-function and mechanistic studies.
Biochimie. 156:12-21; 2019.
514. Mohan S, Moffett RC, Irwin N and Flatt PR
Vasopressin receptors in islets enhance glucose tolerance, pancreatic beta-cell secretory function, proliferation and survival.
Biochimie 158: 191-198; 2019.
515. Sarnobat D, Moffett RC, Gault VA, Tanday N, Reimann F, Gribble FM, Flatt PR, Irwin N.
Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic GluCreERT2;ROSA26-eYFP mice.
Peptides. 2019 Nov 16:170205. doi: 10.1016/j.peptides.2019.170205.
516. Lafferty RA, Tanday N, McCloskey A, Bompada P, De Marinis Y, Flatt PR, Irwin N.
Peptide YY (1-36) peptides from phylogenetically ancient fish targeting mammalian neuropeptide Y1 receptors demonstrate potent effects on pancreatic β -cell function, growth and survival.
Diabetes Obes Metab. 22: 404-416; 2019
517. Hasib A, Khan D, Craig SL, Gault VA, Flatt PR, Irwin N.
Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice.
Eur J Pharmacol. 2019 Dec 15;865:172733. doi: 10.1016/j.ejphar.2019.172733.

518. Perry RA, Craig SL, Ng MT, Gault VA, Flatt PR, Irwin N.
Characterisation of glucose-dependent insulinotropic polypeptide receptor antagonists in rodent pancreatic beta cells and mice.
Clin Med Insights Endocrinol Diabetes. 2019 Sep 12;12:1179551419875453. doi: 10.1177/1179551419875453.
519. Mansur SA, Mieczkowska A, Flatt PR, Chappard D, Irwin N, Mabilieu G.
The GLP-1 receptor agonist exenatide ameliorates bone composition and tissue material properties in high fat fed diabetic mice.
Front Endocrinol (Lausanne). 2019 Feb 12;10:51. doi: 10.3389/fendo.2019.00051.
520. Mansur SA, Mieczkowska A, Flatt PR, Chappard D, Irwin N, Mabilieu G.
Sitagliptin alters bone composition in high-fat-fed mice.
Calcif Tissue Int. 2019 Apr;104(4):437-448. doi: 10.1007/s00223-018-0507-0.
521. Vyavahare SS, Mieczkowska A, Flatt PR, Chappard D, Irwin N, Mabilieu G.
GIP analogues augment bone strength by modulating bone composition in diet-induced obesity in mice.
Peptides. 2019 Nov 22;170207. doi: 10.1016/j.peptides.2019.170207.
522. McCloskey AG, Miskelly MG, Moore CBT, Nesbit MA, Christie KA, Owlabi AI, Flatt PR, McKillop AM
CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell function.
Peptides. 2020; 125:170251. doi:10.1016/j.peptides.2019.170251
523. O'Harte FPM, Parthasarathy V, Flatt PR.
Chronic apelin analogue administration is more effective than established incretin therapies for alleviating metabolic dysfunction in diabetic db/db mice.
Mol Cell Endocrinol. 2020; 504:110695. doi:10.1016/j.mce.2019.110695
524. Graham GV, McCloskey A, Abdel-Wahab YH, Conlon JM, Flatt PR.
A long-acting, dual-agonist analogue of lamprey GLP-1 shows potent insulinotropic, β -cell protective, and anorexic activities and improves glucose homeostasis in high fat-fed mice.
Mol Cell Endocrinol. 2020; 499:110584. doi:10.1016/j.mce.2019.110584
525. Musale V, Guilhaudis L, Abdel-Wahab YHA, Flatt PR, Conlon JM.
Insulinotropic activity of the host-defense peptide frenatin 2D: Conformational, structure-function and mechanistic studies.
Biochimie. 2019; 156:12-21. doi:10.1016/j.biochi.2018.09.008
526. Tanday N, Irwin N, Flatt PR, Moffett RC.
Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta-to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
Biochem Pharmacol. 2020 Jul;177:114009. doi: 10.1016/j.bcp.2020.114009.
527. Tanday N, Flatt PR, Irwin N, Moffett RC.
Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetes.
J Endocrinol. 2020 Apr;245(1):53-64. doi: 10.1530/JOE-19-0451.
528. Gobron B, Bouvard B, Vyavahare S, Blom LV, Pedersen KK, Windeløv JA, Boer GA, Harada N, Zhang S, Shimazu-Kuwahara S, Wice B, Inagaki N, Legrand E, Flatt PR, Chappard D, Hartmann B, Holst JJ, Rosenkilde MM, Irwin N, Mabilieu G.

Enteroendocrine K cells exert complementary effects to control bone quality and mass in mice.

J Bone Miner Res. 35(7):1363-1374; 2020

529. Hannan JMA, Ansari P, Azam S, Flatt PR, Abdel Wahab YHA. Effects of *Spirulina platensis* on insulin secretion, dipeptidyl peptidase IV activity and both carbohydrate digestion and absorption indicate potential as an adjunctive therapy for diabetes [published online ahead of print, 2020 Jun 10]. Br J Nutr. 2020;1-14. doi:10.1017/S0007114520002111
530. Graham GV, Conlon JM, Abdel-Wahab YH, Flatt PR. Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities. Eur J Pharmacol. 2020; 878:173101. doi:10.1016/j.ejphar.2020.173101
531. Ansari P, Azam S, Hannan JMA, Flatt PR, Abdel Wahab YHA. Anti-hyperglycaemic activity of *H. rosa-sinensis* leaves is partly mediated by inhibition of carbohydrate digestion and absorption, and enhancement of insulin secretion. J Ethnopharmacol. 2020; 253:112647. doi:10.1016/j.jep.2020.112647
532. McCloskey AG, Miskelly MG, Flatt PR, McKillop AM. Pharmacological potential of novel agonists for FFAR4 on islet and enteroendocrine cell function and glucose homeostasis. Eur J Pharm Sci. 2020; 142:105104. doi:10.1016/j.ejps.2019.105104
533. Lafferty RA, Tanday N, Flatt PR, Irwin N. Development and characterisation of a peptidergic N- and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes induction. Biochim Biophys Acta Gen Subj. 2020 Jan 30;1864(5):129543. doi: 10.1016/j.bbagen.2020.129543.
534. Craig SL, Perry RA, Vyavahare SS, Ng MT, Gault VA, Flatt PR, Irwin N. A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice. Biochem Pharmacol. 2020 Jan;171: 113723. doi: 10.1016/j.bcp.2019.113723.
535. Lafferty RA, Tanday N, Flatt PR, Irwin N. Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activity. Metabolism. 2020 Oct ;111:154339. doi: 10.1016/j.metabol.2020.154339. Epub 2020 Aug 7. PMID: 32777442.
536. English A, Craig SL, Flatt PR, Irwin N. Individual and combined effects of GIP and xenin on differentiation, glucose uptake and lipolysis in 3T3-L1 adipocytes. Biol Chem. 2020, Oct 25;401(11):1293-1303. doi: 10.1515/hsz-2020-0195. PMID: 32769216.
537. Tanday N, Moffett RC, Gault VA, Flatt PR, Irwin N. Enzymatically stable analogue of the gut-derived peptide xenin on beta-cell transdifferentiation in high fat fed and insulin-deficient *Ins1Cre* ^{+/+} ;*Rosa26-eYFP* mice. Diabetes Metab Res Rev. 2021 Mar;37(3):e3384. doi: 10.1002/dmrr.3384. Epub 2020 Aug 18. PMID: 32662136.
538. Tanday N, Irwin N, Moffett RC, Flatt PR, O'Harte FPM.

- Beneficial actions of a long-acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation.
Diabetes Obes Metab. 2020 Dec;22(12):2468-2478. doi: 10.1111/dom.14177. Epub 2020 Sep 21. PMID: 32844576.
539. Graham GV, McLaughlin C, Flatt PR.
Role of exendin-4 in Gila monster – further lessons for human GLP-1 therapy?
Diabetes Obes Metab. 2020 Dec;22(12):2509-2511. doi: 10.1111/dom.14171. Epub 2020 Sep 14. PMID: 33462968.
 540. Ansari P, Hannon-Fletcher MP, Flatt PR, Abdel-Wahab YHA.
In vitro and *in vivo* effects of 22 traditional anti-diabetic medicinal plants on DPP-IV enzyme activity and glucose homeostasis in high-fat fed obese diabetic rats.
Bioscience Rep., 2021 Jan 29;41(1):BSR20203824. doi: 10.1042/BSR20203824.
PMID: 33416077; PMCID: PMC7823188.
 541. Ansari P, Hannan JMA, Azam S, Flatt PR, Harriott P, Abdel-Wahab YHA.
Evaluation of the antidiabetic and insulin releasing effects of *A. squamosa*, including isolation and characterization of active phytochemicals.
Plants, 2020 Oct 12;9(10):1348. doi: 10.3390/plants9101348. PMID: 33053901; PMCID: PMC7601933.
 542. Ansari P, Hannan JMA, Azam S, Flatt PR, Harriott P, Abdel-Wahab YHA.
Anti-hyperglycaemic and insulin releasing effects of *Camellia sinensis* leaves and isolation and characterization of active compounds.
Br J Nutr., 2020 Dec 17;1-15. doi: 10.1017/S0007114520005085. Epub ahead of print.
PMID: 33331251
 543. Ansari P, Hannan JMA, Azam S, Flatt PR, Harriott P, Abdel-Wahab YHA.
Insulinotropic and antidiabetic properties of *Eucalyptus citriodora* leaves and isolation of bioactive phytochemicals.
J Pharm Pharmacol. 2021 Mar 23:rgab030. doi: 10.1093/jpp/rgab030. Epub ahead of print.
PMID: 33755147.
 544. Musale V, Moffett RC, Owolabi B, Conlon JM, Flatt PR, Abdel-Wahab YHA.
Mechanisms of action of the anti-diabetic of peptide [S4K]CPF-AM1 in *db/db* mice.
J Mol Endocrinol. 2021 Feb;66(2):115-128. doi: 10.1530/JME-20-0152. PMID: 33252358.
 545. Sarnobat D, Moffett RC, Tanday N, Reimann F, Gribble FM, Flatt PR, Tarasov AI.
Antidiabetic drug therapy alleviates type 1 diabetes in mice by promoting pancreatic α -cell transdifferentiation.
Biochem Pharmacol, 2020 Dec;182:114216. doi: 10.1016/j.bcp.2020.114216. Epub 2020 Sep 11. PMID: 32926875.
 546. Musale V, Moffett RC, Conlon JM, Flatt PR, Abdel-Wahab YH.
Beneficial actions of the [A14K] analog of the frog skin peptide PGLa-AM1 in mice with obesity and degenerative diabetes: A mechanistic study.
Peptides. 2021 Feb;136:170472. doi: 10.1016/j.peptides.2020.170472. Epub 2020 Dec 15.
PMID: 33338546.
 547. Graham GV, Conlon JM, Moffett RC, Abdel-Wahab YH, Flatt PR.
Effects of long-acting analogues of lamprey GLP-1 and paddlefish glucagon on α - to β -cell transdifferentiation in an insulin-deficient transgenic mouse model.
J Pept Sci. 2021 Apr 11:e3328. doi: 10.1002/psc.3328. Epub ahead of print. PMID:

33843129.

548. Mohan S, McCloskey AG, McKillop AM, Flatt PR, Irwin N, Moffett RC
Development and characterisation of novel, enzymatically stable oxytocin analogues with beneficial antidiabetic effects in high fat fed mice.
Biochim Biophys Acta Gen Subj. 2021 Mar;1865(3):129811. doi: 10.1016/j.bbagen.2020.129811. Epub 2020 Dec 10. PMID: 33309687.
549. Craig SL, Gault VA, Flatt PR, Irwin N
The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin
Biochem Pharmacol. 2021 Jan;183:114355. doi: 10.1016/j.bcp.2020.114355. Epub 2020 Dec 3. PMID: 33279496.
550. Lafferty RA, Tanday N, Moffett RC, Reimann F, Gribble FM, Flatt PR, Irwin N.
Positive effects of NPY1 receptor activation on islet structure are driven by pancreatic alpha- and beta-cell transdifferentiation in diabetic mice.
Front Endocrinol (Lausanne). 2021 Feb 25;12:633625. doi: 10.3389/fendo.2021.633625. PMID: 33716983; PMCID: PMC7949013.
551. Tanday N, English A, Lafferty RA, Flatt PR, Irwin N.
Benefits of sustained upregulated unimolecular GLP-1 and CCK receptor signalling in obesity-diabetes.
Front Endocrinol (Lausanne). 2021 May 14;12:674704. doi: 10.3389/fendo.2021.674704. PMID: 34054734; PMCID: PMC8160446.
552. Ansari P, Hannan JMA, Azam S, Flatt PR, Harriott P, Abdel-Wahab YHA.
Identification of multiple pancreatic and extra-pancreatic pathways underlying the glucose lowering actions of *Acacia arabica* bark in type-2 diabetes and isolation of active phytoconstituents.
Plants (Basel). 2021 Jun 11;10(6):1190. doi: 10.3390/plants10061190. PMID: 34208010; PMCID: PMC8230611.
553. Mohan S, Flatt PR, Irwin N, Moffett RC
Weight reducing, lipid lowering and antidiabetic activities of a novel AVP analogue acting at V1a and V1b receptors in high fat fed mice
Diabetes Obes Metab. 2021 Jun 9. doi: 10.1111/dom.14462. Epub ahead of print. PMID: 34105240.
554. Sarnobat D, Moffett RC, Flatt PR, Tarasov AI.
Effects of first-line diabetes therapy with biguanides, sulphonylurea and thiazolidinediones on the differentiation, proliferation and apoptosis of islet cell populations.
J Endocrinol Invest. 2021 Jun 30. doi: 10.1007/s40618-021-01620-6. Epub ahead of print. PMID: 34191257.
555. Perry RA, Craig SL, Gault VA, Flatt PR, Irwin N.
A novel neurotensin/xenin fusion peptide enhances β -cell function and exhibits antidiabetic efficacy in high-fat fed mice.
Biosci Rep. 2021 Aug 27;41(8):BSR20211275. doi: 10.1042/BSR20211275. PMID: 34370015.
556. Mohan S, Lafferty R, Tanday N, Flatt PR, Moffett RC, Irwin N.
Beneficial impact of Ac3IV, an AVP analogue acting specifically at V1a and V1b receptors, on diabetes islet morphology and transdifferentiation of alpha- and beta-cells.

- PLoS One. 2021 Dec 20;16(12):e0261608. doi: 10.1371/journal.pone.0261608. PMID: 34929019; PMCID: PMC8687525.
557. Mohan S, Lafferty RA, Flatt PR, Moffett RC, Irwin N. Ac3IV, a V1a and V1b receptor selective vasopressin analogue, protects against hydrocortisone-induced changes in pancreatic islet cell lineage. *Peptides*. 2022 Feb 22;152:170772. doi: 10.1016/j.peptides.2022.170772. Epub ahead of print. PMID: 35202749.
 558. Ansari P, Flatt PR, Harriott P, Abdel-Wahab YHA. Insulin secretory and antidiabetic actions of *Heritiera fomes* bark together with isolation of active phytochemicals. *PLoS One*. 2022 Mar 3;17(3):e0264632. doi: 10.1371/journal.pone.0264632. PMID: 35239729; PMCID: PMC8893667.
 559. Sarnobat D, Charlotte Moffett R, Flatt PR, Irwin N, Tarasov AI. GABA and insulin but not nicotinamide augment α - to β -cell transdifferentiation in insulin-deficient diabetic mice. *Biochem Pharmacol*. 2022 May;199:115019. doi: 10.1016/j.bcp.2022.115019. Epub 2022 Mar 28. PMID: 35358478.
 560. Franklin ZJ, Lafferty RA, Flatt PR, McShane LM, O'Harte FPM, Irwin N. Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice. *Biochimie*. 2022 Apr 16;199:60-67. doi: 10.1016/j.biochi.2022.04.005. Epub ahead of print. PMID: 35439540.
 561. Sarnobat D, Charlotte Moffett R, Flatt PR, Irwin N, Tarasov AI. GABA and insulin but not nicotinamide augment α - to β -cell transdifferentiation in insulin-deficient diabetic mice. *Biochem Pharmacol*. 2022 May;199:115019. doi: 10.1016/j.bcp.2022.115019. Epub 2022 Mar 28. PMID: 35358478.
 562. Franklin ZJ, Lafferty RA, Flatt PR, McShane LM, O'Harte FPM, Irwin N. Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice. *Biochimie*. 2022 Aug;199:60-67. doi: 10.1016/j.biochi.2022.04.005. Epub 2022 Apr 16. PMID: 35439540.
 563. Chen B, Du YR, Zhu H, Sun ML, Wang C, Cheng Y, Pang H, Ding G, Gao J, Tan Y, Tong X, Lv P, Zhou F, Zhan Q, Xu ZM, Wang L, Luo D, Ye Y, Jin L, Zhang S, Zhu Y, Lin X, Wu Y, Jin L, Zhou Y, Yan C, Sheng J, Flatt PR, Xu GL, Huang H. Maternal inheritance of glucose intolerance via oocyte TET3 insufficiency. *Nature*. 2022 May;605(7911):761-766. doi: 10.1038/s41586-022-04756-4. Epub 2022 May 18. PMID: 35585240.
 564. Tanday N, Lafferty RA, Flatt PR, Irwin N. Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists. *Diabetes Obes Metab*. 2022 Dec;24(12):2353-2363. doi: 10.1111/dom.14821. Epub 2022 Aug 11. PMID: 35848461; PMCID: PMC9804730.
 565. Lafferty RA, McShane LM, Franklin ZJ, Flatt PR, O'Harte FPM, Irwin N. Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed mice. *J Endocrinol*. 2022 Sep 14;255(2):91-101. doi: 10.1530/JOE-22-0106. PMID: 36005280; PMCID: PMC9513641.
 566. Sridhar A, Khan D, Abdelaal M, Elliott JA, Naughton V, Flatt PR, Le Roux CW, Docherty NG, Moffett CR. Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats. *PLoS One*.

2022 Sep 22;17(9):e0274788. doi: 10.1371/journal.pone.0274788. PMID: 36137097; PMCID: PMC9499270.

567. Sarnobat D, Lafferty RA, Charlotte Moffett R, Tarasov AI, Flatt PR, Irwin N. Effects of artemether on pancreatic islet morphology, islet cell turnover and α -cell transdifferentiation in insulin-deficient GluCreERT2;ROSA26-eYFP diabetic mice. *J Pharm Pharmacol*. 2022 Nov 25;74(12):1758-1764. doi: 10.1093/jpp/rgac075. PMID: 36206181.
568. Khan D, Ojo OO, Woodward OR, Lewis JE, Sridhar A, Gribble FM, Reimann F, Flatt PR, Moffett RC. Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice. *Biomolecules*. 2022 Nov 23;12(12):1736. doi: 10.3390/biom12121736. PMID: 36551163; PMCID: PMC9775379.
569. McCloskey AG, Miskelly MG, Lafferty RA, Flatt PR, McKillop AM. Antidiabetic actions of GPR55 agonist Abn-CBD and sitagliptin in obese-diabetic high fat fed mice. *Biochem Pharmacol*. 2023 Feb;208:115398. doi: 10.1016/j.bcp.2022.115398. Epub 2022 Dec 26. PMID: 36581052.
570. Turbitt J, Brennan L, Moffett RC, Flatt PR, Johnson PRV, Tarasov AI, McClenaghan NH. NKCC transport mediates the insulinotropic effects of taurine and other small neutral amino acids. *Life Sci*. 2023 Mar 1;316:121402. doi: 10.1016/j.lfs.2023.121402. Epub 2023 Jan 18. PMID: 36669678.
571. McKillop AM, Miskelly MG, Moran BM, Flatt PR. Incretins play an important role in FFA4/GPR120 regulation of glucose metabolism by GW-9508. *Life Sci*. 2023 Apr 1;318:121475. doi: 10.1016/j.lfs.2023.121475. Epub 2023 Feb 7. PMID: 36754346.

14 March 2023